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ABSTRACT 
 
One of the several differences between a normal and a neoplastic cell is that there is a 
physiological limit to the number of possible cell replications in the former, whereas it appears to 
be unlimited in the latter. For this reason, cancer cells are thought to undergo a phenomenon of 
immortalization. 
The chromosome extremities contain structurally defined elements called telomeres. In 
normal somatic cells, each mitotic cycle leads to a reduction of telomere length until a critical 
point is reached. Telomere erosion to this critical length presents a signal for the cell to arrest 
further divisions and to undergo cellular senescence or to activate apoptosis. Telomeres that 
avoid critical shortening could, theoretically, replicate endlessly, thereby immortalizing the cell. 
One mechanism to restore telomere length is the activation of a specific reverse 
transcriptase called telomerase. The telomerase is a ribonucleoprotein that contains a 9-base-pair 
RNA template to rapidly construct telomeric repeats. Upregulation of the telomerase enzyme 
provides immortalizing capacity to neoplastic cells.  
Based on the hypothesis that telomerase is a specific marker of neoplastic tissues, the 
development of methods to detect its activity may represent an accurate, non-invasive diagnostic 
and prognostic tool. 
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CHAPTER 1.  INTRODUCTION 
One of several differences between normal and neoplastic cells is that there is a 
physiological limit to the number of possible cell replications in the former, whereas it appears to 
be unlimited in the latter. For this reason, cancer cells are thought to undergo a phenomenon of 
immortalization. The chromosome extremities contain structurally defined elements called 
telomeres. Telomeres consist of tandem hexanucleotide repeats of the non-coding sequence 
TTAGGG. In normal somatic cells, each mitotic cycle leads to a reduction of telomere length 
until a critical point is reached. Telomere erosion to this critical length presents a signal for the 
cell to arrest further divisions and to undergo cellular senescence or to activate apoptosis. 
Telomeres that avoid critical shortening could, theoretically, replicate endlessly, thereby 
immortalizing the cell. 
The most important mechanism to maintain telomere length is the activation of a specific 
reverse transcriptase called telomerase. The telomerase enzyme is a ribonucleoprotein complex 
that contains an RNA component within which lies an 11-base pair RNA template (5’-
CUAACCCUAAC) complementary to the human telomere sequence (TTAGGG)n. Thus, new 
telomere sequences are quickly constructed. Up-regulation of the telomerase enzyme provides 
immortalizing capacity to neoplastic cells. 
Based on the hypothesis that telomerase is a specific marker of neoplastic tissues, the 
development of methods to detect its activity may provide an accurate, non-invasive diagnostic 
and prognostic tool. The purpose of this project is to compare two different methods to detect 
telomerase activity in normal, hyperplastic and neoplastic lymphocytes in order to assess the best 
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method with regard to sensitivity and specificity. Our results should contribute to the 
development of a useful diagnostic tool for veterinary medicine. 
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CHAPTER 2. LITERATURE REVIEW 
Telomere Nature and Function 
The term “telomere” was coined by Muller and McClintock, etymologically derived from 
two Greek words: telos (end) and meros (part) (Blackburn, 1996). These two scientists were 
noteworthy because they were the first to understand the importance of telomeres in the 
maintenance of chromosome stability and integrity (Rhyu., 1995). As the telomere is the end of 
linear chromosomes, they are present only in eukaryotic cells. Telomeres give chromosomes 
stability and protect from enzymatic degradation and prevent fusion of chromosome ends.  
The first molecular characterization of telomeres was completed in the 1970s (Blackburn 
and Gale, 1978) in the ciliate protozoon Tetrahymena thermophilus. Ciliates have been utilized 
extensively for telomere studies because they contain millions of independent DNA molecules 
and therefore, millions of telomeres in their macronucleus. It has been shown that Tetrahymena 
telomeres are made of TTGGGG sequences, repeated about 70 times. The G rich strand runs in 
the 5’-3’direction and extends for a brief tract beyond the C rich complementary strand.  
As in Tetrahymena, the 5’-3’ helix in vertebrates is G rich and extends 12-16 nucleotides 
beyond the complementary strand end (Blackburn., 1990). Telomeres give stability to 
chromosomes and protect from enzymatic degradation, prevent the fusion of the extremities with 
other chromosomes but, above all, their structure allow the double helix DNA, placed at the end 
of chromosomes, to be completely replicated.  
Beyond their role in cell replication and chromosomal capping, telomeres have been 
proposed to participate in meiotic chromosome segregation and in the organization of the 
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nucleus. Observations of both somatic and meiotic cells suggest that the position of telomeres 
within the nucleus is highly specific and dependent on interactions of telomeres with the nuclear 
envelope (Dernburg et al., 1995). Telomeres sequences and length vary according to species 
(Table 1). In certain ciliates telomeres achieve 36 bp while in human beings and in other 
vertebrates the sequence TTAGGG is repeated to provide a total telomere length of 8-14 Kbp. In 
mice, telomeres can extend to150 Kbp (Dash et al., 1997). Within a given species, the estimated 
length of telomeric DNA varies from 2 to 20 Kbp, depending on factors such as tissue type and 
age of the organism (Jiao and Li, 2002). The number of repetitions varies between cells of the 
same organism, and even varies from chromosome to chromosome in the same cell.  
Telomeres of a species may stabilize chromosomes of other species even if they have 
different sequences of bases. Telomere sequences of the yeast Saccharomyces cerevisae added, 
in vivo, to the ones of the ciliate Tetrahymena thermophilus resulted in appropriate telomere 
function.  
To set up a functional telomere, a telomeric DNA is not sufficient but interaction with 
specific proteins is necessary. Among these, proteins that bind specifically to the single helix 
telomeric tract and proteins that bind to double helix telomeric repetitions have been detected; 
among the latter, the best characterized is Repressor Activator Protein 1 (RAP1) in 
Saccharomyces cerevisae and Telomeric Repeat Factors (TRF1 and TRF2) in human 
(Mondello., 1998).  
In Saccharomyces cerevisae RAP1 is a protein that binds with a periodicity of about 18 
base pairs along all the double strand telomeric DNA (in this species about 300 bp). Repressor 
activator protein one is thought to be a negative regulator of telomerase activity. Mutations in 
RAP1 that alter the DNA binding domain or alter RAP1 expression cause an uncontrolled 
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telomere elongation. Recent results indicate that the number of RAP1 molecules bound to 
telomeres is important for the regulation of telomere length. The cell can “count” the number of 
RAP1 molecules bound to DNA and based on that number can institute or repress telomeric 
repetition. It is presumed that RAP1 signaling is of a structural nature. Thus, binding of the 
appropriate number of RAP1 molecules to telomeres would make the chromosome extremities 
inaccessible to telomerase. There are other proteins acting in conjunction with RAP1 that 
contribute to uncontrolled telomeric elongation.  
In human beings, two telomeric DNA associated proteins have been discovered. They are 
called telomeric repeat factors (TRF1 and TRF2). Telomeric repeat factor one is involved in the 
regulation of telomeric length and, as is the case in RAP1, acts as a negative modulator to 
prevent telomerase access to telomeres of the appropriate range of length. Previous work (Van 
Steensel and De Lange., 1997) showed that long term TRF1 overexpression in a telomerase 
positive cell line could lead to a gradual and progressive shortening of telomeres, on the other 
hand, telomeric elongation was induced by mean of the expression  of a TRF1 dominant negative 
mutant that was able to inhibit the binding of a wild type TRF1 to telomeres (Van Steensel and 
De Lange., 1997). These experimental results identify TRF1 as an inhibitor of telomeric 
elongation and point out that this molecule is implicated in the negative feed-back mechanism 
that stabilizes the length of telomeres. The binding of TRF2 to telomeres seems to be necessary 
to protect the extremities of chromosomes from end-to-end fusion and to maintain the 
individuality of single chromosomes. If the bind of wild type TRF2 to telomeres is prevented by 
mean of overexpression of a mutant TRF2, the formation of dicentric chromosomes as a result of 
end to-end-fusions, is observed (Mondello, 1998). 
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The End-Replication Problem 
The replication of the 3’ end of the chromosome presents a problem in biology due to the 
polarity of DNA polymerase. One of the main reasons why linear chromosomes have telomeres 
is to circumvent the loss of DNA that takes place when the 5’ terminus of a chromosome is 
replicated. This loss of 5’ terminal sequence occurs because all known DNA polymerases require 
a pre-existing primer molecule in order to initiate DNA synthesis (Levy et al.,1992). In non-
telomeric DNA replication, the strand that is continually replicated is called the “leading strand” 
whereas the complementary strand is called “lagging”. To replicate the lagging strand, DNA 
polymerase III utilizes primers generated by RNA primases. This results in the creation of short 
DNA fragments called Okazaki fragments. The RNA primer template is subsequently degraded 
by DNA polymerase I, and the DNA fragments are extended and ligated by ligases to create a 
continuous DNA strand. The terminal RNA primer removal on the lagging strand, cannot be 
replicated and extended by this Okazaki fragment method. Thus, chromosomal DNA is 
shortened at the 3’ extremity of all chromosome ends with each round of cell replication. 
Removal of this RNA primer results in the daughter strand being 8-16 nucleotides shorter than 
the parental strand. Therefore, there is a progressive loss of the end of chromosomes with each 
cell division. It has been proposed that this loss may play a role in the aging process (Fig. 2-3).  
The enzyme telomerase solves this "end-replication problem" by adding DNA to the end 
of a chromosome by a process that is independent of the classical DNA replication machinery 
(Klapper et al.,2001). In addition, it now appears that the 3’ single stranded telomere overhang is 
the template for telomerase activity. Telomerase is a specialized reverse transcriptase that 
contain an internal RNA template. The RNA template contains sequences that are 
complementary to the 3’overhang G-rich strand of the telomeric repeat. In normal somatic cells, 
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where telomerase is not active, the telomeres shorten with each cell division while in germ line 
cells, where telomerase is constitutively expressed, telomere length is maintained at a stable 
length. During addition of new telomeric DNA, the RNA template fragment aligns with the 3’ 
overhang end of the chromosome, extending the end of the pre-existing DNA. To generate 
multiple repeats, the enzyme then translocates to the new chromosome terminus, realigns with 
the template region and the process is repeated (Klapper et al.,2001). As stated, a certain amount 
of telomeric DNA is lost during each mitotic division. Terminal restriction fragments analysis 
(TRF Assay) (Van Steensel and De Lange., 1997) demonstrated that chromosomes lose about 50 
up to 200 nucleotides from the telomere per each cellular mitosis. This mechanism could 
represent a “mitotic clock” by which cells may “count” the number of division until critical 
telomeric shortening causes entrance into cellular senescence and blocks further divisions. 
Telomerase Nature and Function 
The standard mechanisms that permit chromosome duplication during cell division are 
unable to do a complete job. When DNA polymerases copy the two original or “parental” DNA 
strands, each new generated strand is shortened at one extremity. This is because of the polarity 
in DNA polymerase and the need for Okazaki priming RNA fragments, as previously discussed. 
When cells are not able to repair this defect caused by the duplicating mechanism, chromosomes 
would shorten continually (Greider and Blackburn., 1996). Experiments performed by these 
authors on telomeric DNA of Tetrahymena thermophilus detected an enzymatic activity that 
added sequences to the terminal DNA strands. Human telomerases work well on yeast telomere, 
suggesting that this functional conservation is not limited to lower eukaryotes (Blackburn., 
1990). This RNA dependent enzyme is a terminal tranferase called telomerase. Telomerase is a  
ribonucleoprotein complex in which the RNA molecule contains a species specific sequence 
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complementary to the G-rich sequence of the telomere, which acts as a template for the synthesis 
of additional telomeric repeats. 
Cellular extracts of Tetrahymena thermophilus, have high telomerase activity because  of 
the large number of telomeres in the nucleus of this organism (up to 40,000 per macronucleus). 
When T. thermophilus is treated with RNAase A, the capability to extend the telomere ends is 
lost. This points out the importance of the telomerase RNA template fragment to telomerase 
complex function (Rhyu.,1995). When RNAase A treatment was performed on immortalized, 
telomerase positive HeLa cells, telomerase activity was also lost. Thus, the HeLa cell 
experiments also supported the observation of the ribonucleoprotein nature of telomerase (Rhyu., 
1995). HeLa cells are a cervical carcinoma cell line developed in the 1940s. They are commonly 
used as a research tool in cancer and cell biology. HeLa cells are characterized by profoundly 
abnormal karyotype and morphological and biochemical differences compared to those of 
diploid cells (Holliday., 1995). 
Telomerase is, therefore, classified as a reverse transcriptase, similar to the reverse 
transcriptase of Retroviruses. A reverse transcriptase is an unusual DNA polymerase that uses 
both RNA and DNA as a template; in viruses it is encoded by viral RNA and a molecule of 
enzyme is placed within each viral capsid during viral particle production. As the viral single 
strand RNA enters the cell, the reverse transcriptase contained in the capsid first makes a DNA 
copy of the RNA strand to create a hybrid DNA-RNA helix that is later used by the same 
enzyme to make a double stranded molecule of DNA. This double stranded DNA is subsequently 
inserted into the host genome (Alberts et al., 1995). 
As stated previously, telomerase uses the 3’ extremity of telomeric DNA as a starting 
point for extension by synthesis of repeated units of the template sequence contained in the RNA 
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subunit. This enzymatic complex creates multiple hexanucleotide repeats per cell replication 
cycle. Once the G-rich helix has been extended, the complementary strand is subsequently 
synthesized by standard DNA polymerase (Fig.4). 
The absence of telomerase activity in normal somatic cells and its reactivation in 
neoplastic cells indicates an important role in cellular senescence and tumorigenesis. Telomerase 
is essential for chromosome end replication. It accomplishes this function with the aid of a 
variety of ancillary factors. Those ancillary factors guide telomerase in localization and in 
performance (Mondello., 1998). Telomerase reverse transcriptase protein and telomerase RNA 
do not seem to be the only two molecules involved in the ribonucleoproteic complex responsible 
for telomerase activity. Recently in Tetrahymena termophilus, genes codifing for two proteins 
(p80 and p95) associated to the telomerase RNA have been cloned. 
The Catalytic Subunit of Telomerase 
The most important and rate limiting component of human telomerase is the catalytic 
subunit hTERT and its expression correlates with telomerase activity (Liu et al.,2000; Nakayama 
et al.,1998). The catalytic activity that synthesizes telomeric DNA by copying the RNA 
template, is carried out by the protein subunit of the enzyme. The gene that encodes the catalytic 
subunit of telomerase (TRT) has been cloned (Lingner et al., 1997). This gene contains critical 
domains in which the introduction of a single amino acid substitution results in telomere 
shortening and cell death. This research points out that these domains are essential for the 
catalysis of telomeric elongation (Mondello, 1998). To date, hTERT mRNA has been detected in 
most of tumors with telomerase activities.  
Restoring telomerase activity in human diploid cells is possible inserting the catalytic 
subunit (Bodner et al.,1998). To evaluate if telomerase activity was able to extend cell life span, 
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genetically modified hTRT proteins were inserted in normally hTRT (-) cells such as pigmented 
epithelial cells of retina and preputial fibroblasts. Based on the presence of telomerase activity in 
almost 90% of neoplastic cells, these authors compared telomerase expression in both the 
pigmented epithelial cells and preputial fibroblasts with control cells derived from lung cancer. 
Telomerase was highly expressed in both the experimental samples after the introduction of the 
genetically modified hTRT. Based on these results telomere length in normal hTRT (+) cells was 
measured to investigate the role of the catalytic subunit on its natural substrate, the telomere 
(Bodnar et al.,1998). In hTRT (-) cells, telomeres decreased in length passing from 1.3 up to 0.4 
kbp whereas in the clones examined and modified by mean of catalytic subunit insertion, 
telomeres increased in length of 3.7 and 7.1 kbp respectively for retinal epithelial cells and for 
preputial fibroblasts. To evaluate the telomerase expression effect on normal cells life span, these 
authors compared the growth of hTRT (-) and hTRT (+) clones. Human telomerase reverse 
transcriptase (-) clones showed, as expected, a slowing in their growth leading to senescence. 
Human telomerase reverse transcriptase (+) clones showed a cycle of more than 20 duplications 
compared to the others (Bodnar et al., 1998). The telomerase complex also comprises hTERT-
associated proteins such as Hsp90 and p23, which are required for activity of the enzyme and 
TLP-1, but the function of these proteins is still unknown (Jiao and Li Xin, 2002). 
Neoplastic transformation of human immortalized cells was induced by mean of the 
ectopic expression of hTRT, after the insertion of an association of oncogenes such as SV40 
large T and an oncogenic allele of the ras gene (Hahn et al.,1999). Primary rodent cells are easily 
converted in neoplastic cells by the coexpression of cooperant oncogenes. These experiments, 
however, often failed in human cells indicating some biologic difference between human and 
rodent cells as far as the expression of hTRT and neoplastic transformation. The few successes 
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obtained creating human neoplastic cells were due to the introduction of physical and chemical 
agents to reach immortalization or to the selection of rare spontaneously immortalized cells or to 
the use of whole viral genome (Hahn et al.,1999). An early entrance in the crisis phase was noted 
after just 10 cellular duplications in telomerase (-) human cell population expressing only large T 
and ras. No neoplastic masses developed when human cells expressing only large T or large T 
and ras or large T and hTRT, were introduced in immuno-deficient nude mice observed. On the 
other hand when the cells expressed all of the three genetic elements (large T, hTRT and ras), 
they quickly developed neoplasia if introduced in the same mice (Hahn et al.,1999). The 
conclusion of the work pointed out that the ectopic expression of a definite series of genes (large 
T, ras, hTRT) was sufficient to convert normal human cells. These results start to clarify the 
biochemical pattern that should be elicited to create a neoplastic transformation in normal human 
cells.  
A potentially useful application in tumor diagnosis would be to develop specific 
monoclonal antibodies (MAbs) able to immuno-detect hTERT. Through the hybridoma 
technique clones secreting anti-hTERT antibodies were generated. The MAbs were hTERT-
specific and reactive with native hTERT of human cancer cells presenting single band about 120 
kDa, which was consistent with the weight of 127 kDa hTERT. In this work (Yang et al.,2001), 
the MAbs were used to detect hTERT in human cancer, precancerous and benign lesions and 
results showed that hTERT was expressed in about 80% of human cancers, consistent with those 
of telomerase activity and hTERT mRNA reported (Yuan et al.,2000). 
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Cellular Aging and Immortalization 
Cellular Senescence 
In the current literature cells that have finished their proliferative life span in vitro and 
have reached a terminal post-mitotic state are called senescent cells. This definition originated 
from the belief that the irreversible non-dividing state has a relationship with aging of the 
organism (Macieira-Coelho,1998). 
Death after senescence must be differentiated from death by apoptosis or programmed 
cell death. Although senescence could come before the activation of a “suicide” program in the 
cell, a cause and effect relationship has yet to be established. 
Programmed cell death (apoptosis) is well established in many multicellular organisms. 
Apoptosis “purifies” a tissue from cells that become useless or harmful for the organism. Similar 
phenomena occur also at subcellular level (suicide of mitochondria, i.e., mitoptosis). 
Mitochondria possess a mechanism of self-elimination mediated by the permeability transition 
pore (PTP). Massive mitoptosis results in apoptosis. At the supercellular level things are not so 
different. The massive apoptosis of cells composing an organ should eliminate the organ. This 
process is called organoptosis. An exemple of organoptosis is the disappearance of the tail of a 
tadpole when it becomes a frog. Obviously massive apoptosis in an organ of vital importance 
must lead to death of the entire organism and this is important if the organism is a member of a 
community of other individuals (Skulachev,1997). The programmed death of the organism is 
called “phenoptosis” (Skulachev,2002) and aging seems to be correlated with this phenomenon.  
Many experimental works show the involvement of telomeres in the mechanism of 
cellular senescence (Levy et al.,1992). It has been suggested that the signal for cellular 
senescence originates from a single or a critical number of chromosomes whose telomeres have 
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eroded to insufficient length to function appropriately. These chromosome extremities would be 
recognized by the cell as double strand breaks and could trigger cell cycle control mechanisms 
that eventually block further cell multiplication as if damage to DNA was present. In favor of 
this hypothesis there is the observation that among the agents that transform human cells and 
determine the ability to overcome the senescence there is the SV40 T antigen. This molecule 
binds and inactivates p53, one of the most important factors involved in cell cycle regulation 
after DNA damage (Mondello., 1998). If in the cells was not present a mechanism able to fix this 
deficiency of the replicative system, chromosomes would shorten at each cellular generation and 
the genome would be eroded over time. 
A correspondence between telomere length and replicative capacity of cultured 
fibroblasts has been well established. Cells from fetal tissues and from 90 year old donors have 
been assessed. Telomere length and lifespan of fibroblasts in culture, did not correspond with the 
age of the donor. However a relationship was found, instead, between the number of in vitro 
cellular divisions and the telomere length (Rhyu,1995). The knowledge of the role of telomeres 
and of telomerase in cellular senescence may be very helpful to understand the physiogenesis of 
aging and the pathogenesis of some diseases such as human progeria and Werner’s syndrome.  
Progeria is a rare genetic condition characterized by an appearance of accelerated aging 
in children. Its name is derived from the Greek and means "prematurely old." The disease is 
caused by an autosomal dominant inherited gene. Newborn progeria patients are apparently 
normal but after a variable time they begin to display evidence of rapid and progressive 
senescence. These signs of senescence include thin limbs, baldness, short height, and loss of 
subcutaneous tissue due to degenerative changes occurring at cutaneous, musculoskeletal and 
cardiovascular levels.  
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Werner's syndrome is caused, on the other hand, by an autosomal recessive mutation. 
This syndrome is much less serious than progeria. Affected people are normal for 20- 30 years 
with subsequent progressive changes such as juvenile cataract, diabetes mellitus, loss of 
subcutaneous adipose tissue of the limbs, osteoporosis and increased incidence of neoplasia 
(Hollyday,1995). In patients affected by these two rare diseases, the telomere length has been 
shown to be quite decreased compared to that of normal persons and a consequent chromosome 
instability and increased frequency of mutation has been noted (Dashe et al.,1997). 
Like many important biological functions, aging also is mediated by several molecular 
mechanisms working simultaneously. These mechanisms include: telomere shortening due to 
suppression of telomerase at early stage of embryogenesis; age-related activation of mechanisms 
that induce the synthesis of heat shock proteins in response to appropriate stimuli; incomplete 
suppression of generation of reactive oxygen species  (ROS) with inadequate scavenging of 
already existing ROS. Individually, none of these phenomena can kill the organism but may 
serve to weaken it, which can become crucial under certain conditions. Cells have several 
mechanisms to minimize the damage caused by super-oxide and other free radicals and ROS 
species. Among these defense mechanisms is the multilevel system of defense against ROS as 
well as mechanisms to  prevent the accumulation of semiquinone (CoQH) and similar reductants. 
Additional enzymes decrease the intracellular oxygen concentration to reduce the rate of 
generation of superoxide. In addition to these cellular mechanisms, higher animals have 
physiological supracellular systemic effects, such as a decrease in lung ventilation and capillary 
constriction upon the transition from work to rest, when the demand for oxygen decreases 
(Skulachev,1997). 
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Heat shock proteins are a particular type of repair proteins whose contents increases 
considerably upon cell exposure to environmental conditions that denature protein molecules. In 
response to such stimuli, the cell activates the trimerization of heat-shock factor I (HSF I), a 
specific protein normally present in the cytosol in monomeric form. The HSF I trimer is 
transported to the nucleus where it activates promoters for heat-shock protein genes 
(Skulachev,1997). 
Useful as a biomarker for senescence is also the β-galactosidase activity. Treating both 
hTRT (+) and hTRT (-) clones with this marker that has affinity for senescent cells, it has been 
seen that the majority of cells of the hTRT (-) clone expressed big amounts of β-galactosidase 
whereas scant amounts were expressed by cells of the hTRT (+) clone (Bodnar et al.,1998). 
Cellular Immortalization 
The majority of somatic cells of different mammalians have a limited life span in cell 
culture. After a defined number of divisions, cells incapable of further multiplications enter into 
a phase called "cellular or replicative senescence". In this phase cells are metabolically active 
and can remain in this state also for years if properly supported. However, cells in this phase do 
not respond to mitotic stimuli (Mondello,1998). The concept of immortalization is tightly linked 
to the concept of "senescence". 
Telomerase plays a key role in cellular immortalization. Alternative mechanisms to 
stabilize chromosomes have been shown in experiments on the yeast Kluyveromyces lactis and 
on human immortalized cell lines in which telomerase activity was inhibited. However, for most 
cells re-induction of telomerase expression is required to allow escape from a senescent fate. 
These alternative mechanisms though, are less precise compared to the gradual telomeric 
repetitions elongation performed by telomerase (Rhyu,1995). Telomere length is prone to 
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shorten in all the somatic cells, whereas this does not happen in germ line cells that maintain an 
unchanged telomere length throughout many mitotic divisions (Norton et al.,1996). 
It is possible to immortalize somatic cells by stabilizing their telomeres. Transfecting 
normal embryonal human kidney cells with the tumor antigen SV40T is possible to obtain an 
oncogenic viral protein that increases a cellular lifespan. These cells, eventually, reach a point of 
"crisis" in which most cells die. A small percentage of cells become immortal. During the period 
of somatic cell division in vitro, telomeres shortened progressively and no telomerase activity is 
detected. The few cells capable of overcoming the "crisis" phase to become immortal possess 
reactivated telomerase that restabilizes telomere length. This indicates that even somatic cells 
can multiply endlessly provided that telomere length is maintained, usually through the 
reactivation of telomerase enzyme (Dahse et al., 1997). 
It has been hypothesized that in vitro transformed cells have only a limited lifespan 
extension and continue to lose telomere sequences (Counter et al.,1992). This loss may 
potentially play a role in the proliferative crisis seen of these cells. Telomerase activation and 
telomere stabilization usually occurs during the development of the immortal phenotype. To 
prove this hypothesis, the length and the amount of telomeric DNA, the incidence of dicentric 
chromosomes, and presence of telomerase activity during the lifespan of human kidney SV40 
and Ad5 transformed or non-transformed embryonic cells has been measured. This research 
demonstrated that in the beginning, telomeric sequences were lost in similar amounts in all the 
cellular populations. The process of telomere loss continued uncontrolled in the Ad5 transformed 
populations. These cells had acquired only an extension of lifespan, and ultimately suffered 
death during crisis. In these non-immortalized populations, no telomerase activity was detected 
and the loss of telomeric DNA was associated with an increase in formation of dicentric 
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chromosomes. Populations of Ad5 transformed cells expressed telomerase and telomeric DNA 
stabilization was observed with minimal formation of dicentric chromosomes. Dicentric 
chromosomes increase in number over time in primary fibroblast cultures and this abnormality is 
common to both normal and transformed cells. 
Chromosomes losing the protective effect of telomeric DNA are highly recombinant. 
Cells with shortened telomeres may experience an increased incidence of chromosome 
rearrangements that potentially could derive from end-to-end telomere fusion. In experiments 
using transformed populations these cells had an average of less than one dicentric chromosome 
per 50 metaphases but, during crisis, a significant increase in rearrangement frequency was 
noted. In this work three aspects of cellular immortalization were analyzed. First, extremely short 
chromosomes can induce an increase in dicentric chromosomes formation and cause entrance of 
transformed cells into a crisis phase. Secondarily, in immortalized cells telomere decrement 
ceases and the frequency of dicentric chromosomes stabilizes. Finally, it was noted that 
telomerase activity is not detectable in those populations that undergo telomeric loss but is 
present in immortal cells where telomere length is kept constant. Therefore it was supposed that 
telomerase expression is a requisite for cellular immortalization.  
Of 35 immortalized cell lines, 20 showed expected telomerase activity. The other 15 did 
not demonstrate telomerase activity although they expressed long and stable telomeres. Hybrid 
cell lines, obtained by combining one telomerase positive and one telomerase negative cell line 
have been shown to undergo senescence even while expressing telomerase activity. This 
phenomenon is consistent with the hypothesis that telomerase activation is not essential for 
immortalization. Furthermore, some hybrid clones could achieve immortalization even in the 
absence of telomerase activity. Absence of telomerase activity in two SV40 immortalized cell 
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lines has been observed (Kim et al., 1994). These authors attributed immortalization to the long 
telomeres present in these cells. These results suggest the importance of telomere maintenance 
and stabilization in order for the cell to become immortal, and the importance of telomere 
shortening to potentially trigger cellular senescence. 
Although telomerase activity was not detected in normal primary cell cultures or in viral 
oncogene transfected but non-immortalized cell lines, two hybrid clones of senescent cells 
expressed telomerase activity. This suggests that telomere stabilization is necessary but not 
sufficient to elicit senescence mechanisms, at least in the hybrid clones. Other organisms such as 
the yeast Saccharomyces cerevisae demonstrate telomerase-independent mechanisms to stabilize 
telomeres. Saccharomyces cerevisae uses recombination mechanism by which a non-telomeric 
portion of chromosome recombines in a different region of another chromosome. Research now 
focuses on investigating the presence of these mechanisms in human cells. 
In mouse somatic cells, immortalization can occur spontaneously. The “mortal” 
phenotype of somatic cells is dominant to the “immortal” phenotype (Mondello,1998). In cell 
culture studies it has been shown that cells stop dividing due to the activity of antiproliferative 
mechanisms that contribute to a hypothetical model of cell immortalization. These 
antiproliferative mechanisms induce phases of cell culture kinetics called M1 (mortality stage 1) 
and M2 (mortality stage 2). Stimuli for the activation of M1 include DNA damage signals. The 
cell cycle regulatory genes p53 and pRb are involved in M1, (Table 2). Wild-type p53, along 
with other molecules with genome guardian functions, can activate proliferative arrest signals. 
These signals are activated by detection of telomeric repeat loss or structural variations due to 
telomere erosion (Hiyama et al.,1994). In vitro studies have also shown that M1 can be 
overcome after transformation with viral oncogenes such as SV40 (Morin, 1995). In M1, 
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telomeres are still functional even if cells are telomerease negative. Thus, telomeres continue 
shortening until the “mortality stage 2 or M2 phase is reached. Mortality stage 2 is activated 
when chromosomes lose the protective function of telomeres through cell replication induced 
erosion. Further cell replications are arrested to prevent subsequent chromosomal damage. In this 
phase, most cells are directed to the senescence pathway and then die (Morin,1995). Mortality 
stage 2 can be overcome by telomerase reactivation, chromosome extremity repair, and telomere 
length stabilization. This results in the emergence of immortal cell clones. 
Genetic Changes Associated with Immortalization 
Human somatic cells seem to have 3 terminal proliferative arrest (TPA) states that 
prevent immortalization. The first TPA state to be discovered was senescence. Senescent cells 
can remain viable for long periods of time, indicating that the senescence process is markedly 
different from any form of cell death. Senescent phenotype is dominant over the immortal 
phenotype (Bunn and Tarrant,1980; Pereira and Smith, 1983). This means that the limited 
lifespan of normal cells is a genetically programmed process and that immortal cells have lost 
the function of one or more putative senescence genes usually active in normal cells. The second 
TPA state is referred to as crisis, normal human cells rarely, if ever, become immortalized 
spontaneously in vitro. However, they can be immortalized reliably, although at very low 
frequency, following infection by DNA tumor viruses such as SV40 and papillomavirus (Linder 
and Marshall, 1990). SV40 has been the most commonly used agent to induce immortalization of 
non-hematopoietic human cells. This process consists of two stages, the first stage is a temporary 
lifespan extension. Following introduction of the SV40 DNA encoding the large T antigen and 
other oncoproteins, normal human cells become morphologically transformed and their 
proliferative lifespan increases by approximately 20-60 population doublings (PD) beyond the 
 20
point at which their normal counterparts enter senescence. Usually these cells enter crisis, during 
which no net population increase occurs. The second stage is the acquisition of an unlimited 
proliferative potential. Some of the cells in crisis may resume proliferation and become 
immortal.  
Immortalization is a rare event, occurring at a frequency of between 10-5 (Shay et 
al.,1993) and 10-9. Crisis therefore appears to be the final TPA barrier that needs to be breached 
before cells can become immortal. The abbreviation M1 and M2 have been suggested for 
senescence and crisis respectively (Wright et al.,1999).  
Recent studies have shown the existence of at least one additional TPA state. Introduction 
of a dominant-negative mutant p53 gene permitted fibroblasts to proliferate for a limited number 
of population doublings beyond the point at which their normal counterparts became senescent 
(Fushimi et al.,1997). Evidence that this effect was due to loss of wt p53 function and not due to 
a p53 gain-of-function mutation was provided by experiments using a fibroblast cell line derived 
from a Li-Fraumeni patient. The IIICF fibroblasts contain one wt and one null mutant p53 allele. 
These cells escaped from senescence and proliferated for an additional 32- 35 PD when the wt 
allele was spontaneously deleted or mutated (Rogan et al.,1995). When the same heterozygous 
p53 wt/null-mutant IIICF cells were transformed with SV40 early region genes, the cells 
proliferated for an additional 60-70 PD beyond senescence, before entering crisis (Maclean et 
al.,1994). These studies indicate that fibroblasts in which normal p53 function has been 
abrogated escape temporarily from senescence before entering a TPA state. This “p53-minus 
TPA” state possesses the ability to support PD numbers intermediate between senescence and 
crisis. 
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Methods to Study Telomeres and Telomerase 
By the time the important role of telomeres and telomerase in aging and cancer was 
understood, several methods had been developed to detect and study telomeric chromosomal 
regions and telomerase activity. Several protocols are available to detect TTAGGG telomere 
repeats in situ, including primed in situ (PRINS) (Therkelsen et al.,1995; Krejci and Kock,1998) 
labeling, or fluorescence in situ hybridization (FISH) with RNA- translated (Luderus et al.,1996) 
or nick- translated double stranded DNA (ds DNA) repeat probes (Henderson et al.,1996; Ijdo et 
al.,1991). Long oligonucleotides have proven effective telomere FISH probes (Meyne et 
al.,1994). FISH with short peptide nucleic acid (PNA) telomere probes yield detection 
efficiencies of nearly 100% (Lansdorp et al.,1996; Zijlmans et al.,1997; Martens et al.,1998). 
Telomerase activity may be detected by several protocols. The first methods to be used 
were slow, cumbersome and based on incorporation of specific radioactive dNTPs into the 
telomeric repeats added onto the 3' end of a synthetic primer (Bilaud et al.,1997). These assays 
also were problematic because of very limited sensitivity. In 1994 (Kim et al.,1994) developed a 
polymerase chain reaction (PCR) based telomerase repeat amplification protocol, abbreviated as 
the TRAP assay. This methodology remains one of the most used protocols in telomerase 
research. The TRAP assay increased the speed of detection and drastically improved sensitivity 
by a factor of 104 over the prior radioisotope incorporation method. The TRAP protocol has been 
utilized to evaluate a large variety of human normal, reactive and neoplastic tissues. This early 
research supports the importance of telomerase activity detection as an early diagnostic tool as 
well as a prognostic indicator. The TRAP assay consists of two basic steps. A viable telomerase 
artificially extends polymeric repeats at the 3' end of a synthetic forward primer called TS. The 
telomeric products created in step one are subjected to PCR amplification through the addition of 
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a reverse primer. This results in amplification of a 6 base pair repeat ladder which is detected by 
gel electrophoresis. The TRAP assay, however, is fraught with technical difficulty and is prone 
to either false- negative or false- positive results. Telomerase- negative samples cannot be 
differentiated from telomerase- positive samples containing inhibitors of PCR amplification, thus 
giving false negative results. Furthermore, due to the repetitive structure of the PCR products, 
nonspecific amplification products resulting from staggered annealing of the reverse primer have 
been described (Kim and Wu,1997). The TRAP detection method relies on either radiolabelling 
with autoradiography or staining with ethidium bromide, silver nitrate or SYBR Green J and 
subsequent fluorescent imaging for quantification. Variations on the standard TRAP method 
include a fluorescent detection method in which a fluorescent TRAP reaction mix with a 
fluorescein- labeled TS primer are used. 
Another approach to semiquantify the telomerase activity is the stretch PCR assay. As 
being more quantitative than the standard TRAP assay with this method it is possible to detect 
telomerase activity at the single cell level (Tatematsu et al.,1996).  
A recently developed technique is the TRAP Enzyme-Linked Immunosorbent Assay 
(ELISA). This is a non- radioactive method that omits the gel separation step originally 
described for the TRAP method. An ELISA protocol is used to detect amplification products by 
a colorimetric method utilizing an ELISA-plate reader for semi-quantitation of results. The 
method seems to be useful for sensitive detection of telomerase activity and is especially 
valuable for studying large number of samples. Compared to the conventional TRAP assay, the 
TRAP ELISA is less time consuming because neither gel preparation nor electrophoretic 
separation steps are required. The sensitivity of the assay is equal or superior to that of the 
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conventional TRAP assay. The specificity observed is the same as seen with the conventional 
assay. 
A very recent work (Xu et al.,2002) describes a novel method to measure telomerase 
activity by use of an enzymatic luminometric pyrophosphate (PPi) assay. This method is called 
ELIPA test. The ELIPA method is based on the elongation of telomeric repeats catalyzed by 
telomerase followed by the release of six PPi for each TTAGGG repeat. These PPi are later 
converted to ATP, which is detect by a luciferase bioluminescence system. The ELIPA was 
compared to the TRAP ELISA in a study of 42 lung carcinomas and 27 control normal tissues. 
The lower detection limits of ELIPA for telomerase activity was 5 cells whereas for TRAP 
ELISA was 10 cells; the sensitivity and specificity of ELIPA were 83% and 96%, respectively, 
whereas for TRAP ELISA were 71% and 96% respectively (Xu et al.,2002). 
The advent of TRAP has allowed for the semi-quantitative detection of telomerase from 
limiting sample amounts. Due to the limited quantitative potential, TRAP is not very accurate in 
providing quantitative data. Real Time quantitative analysis is a recent method developed 
adapting the fluorescent-based TRAPeze XL telomerase detection kit with real time polymerase 
chain reaction. Quantitation of telomerase activity using real-time analysis is more precise than a 
gel-based approach because it relies on threshold cycle (Ct) values (Lynne et al.,2002). A 
threshold cycle value is the initial cycle in which PCR product is detectable. Ct values are 
determined during the exponential phase of PCR at relatively low concentrations of PCR product 
before saturation or plateau. This method ensure a more accurate quantification and high 
throughput capabilities improving reliability, assay time, and accuracy of quantitation (Lynne et 
al.,2002). In a different work the real-time quantitative TRAP (RTQ-TRAP) was compared with 
the conventional TRAP in 13 lymphoma samples (Hou et al.,2001). Telomerase activity 
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determined by the RTQ-TRAP method was 9-fold lower than that measured by the TRAP assay. 
This study suggested that the conventional TRAP assay may overestimate telomerase activity in 
tumor samples. The RTQ-TRAP assay may be thus a useful tool to rapidly and precisely quantify 
telomerase activity (Hou et al.,2001). 
A recent study aimed to determine telomerase activity in colorectal carcinoma (CRC) and 
benign colon samples immunohistochemical stained for hTRT. The peroxidase method was used 
in the study. The conclusion of the study pointed out that increased telomerase activity in CRC, 
as demonstrated by hTRT immunostaining, is associated with poorer survival (Wei and 
Younes,2002). 
In a different study (Yang et al.,2002) 3 hybridoma cell lines secreting anti-hTERT 
antibodies, designated as H4, G8 and A11 were generated. The affinity of G8 was stronger than 
that of H4 and A11. Sections from paraffin-embedded blocks of 127 cases of human cancer, 40 
of pre-cancerous and 19 of benign tumors were in situ stained by G8 antibodies. The results 
showed that the neoplastic tissues were 80.31% positive and only 17.5% of pre-cancerous lesions 
presented weak positivity. Negative outcome came from benign tumors. The conclusion of the 
study confirmed the specificity of the G8 Mabs for hTRT (Yang et al.,2002). 
 
Telomerase Activation in Neoplastic Cells 
The loss of cell cycle control caused by mutations in the oncogenes and in the tumor 
suppressor genes, generally leads to cell death by apoptotic mechanisms but sometimes can 
determine the acquisition of uncontrolled cellular proliferation. As stated, telomere length serves 
as a control in the proliferative capacity of cells. 
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Neoplastic cells with telomeres shorter than their normal counterpart have been detected 
in many types of tumor such as neuroblastoma, tumors of endometrium, mammary tumors, lung 
tumors, and leukemias. In all these tumors the shorter the telomeres the more malignant was the 
behavior of the disease. The reason is that neoplastic cells with short telomeres have passed 
through many divisions, accumulating many genetic defects accounting for a more malignant 
phenotype. Once telomeres have reached the critic length, telomerase is activated.  
As mentioned before, telomerase is normally absent in somatic cells whereas is present in 
germ lines to ensure the transmission of intact chromosomes to the future generations 
(Morin,1995). It is moreover present in hematopoietic stem cells, in T and B activated 
lymphocytes and in epithelial cells during regeneration. Furthermore is detectable in 90% of 
neoplastic tissues (Mu and Wei,2002).  
Telomerase activity has not been detected, in benign or premalignant lesions such as 
fibrocystic mastopathy, fibroadenomas, prostatic hyperplasia, meningiomas and leiomyomas. 
Telomerase expression was detected, however, at the first signs of malignancy (Dashe et 
al.,1997). In these cases, the progress of telomerase activity can give information of diagnostic 
significance. Because normal tissues at the edges of the tumor do not express telomerase activity, 
it has been proposed to use telomerase activity as a marker to detect the presence of neoplastic 
cells at the resection margins.  
Telomerase can be a useful diagnostic marker above all in mammary tumors. In one 
study (Hiyama et al., 1994) a fine needle aspiration (FNA) technique was performed in 14 
patients with mammary lesions and high telomerase activity was detected. The histopathological 
examination confirmed the malignant nature of the lesions. In the same work a correlation 
between survival time and telomerase expression was noted in a group of gastric carcinomas. 
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The higher the expression of the enzyme, the shorter the survival time of the patient. In another 
work (Kim et al., 1994), human cells and tissue extracts were examined. Telomerase activity was 
detected in nine immortalized cell lines and in one ovarian carcinoma. Telomerase negative 
resulted four cultures of normal somatic cells and also the carcinomatous area surrounding tissue. 
A correlation between telomerase expression and telomere length in a cell population has 
been hypothesized. To prove this hypothesis the lengths of TRFs in different immortalized cell 
lines used to detect telomerase activity were determined. Although the majority of them had 
short TRFs (< 4 kb), the rest of them had TRFs beyond 10 kb and this was enough to reject the 
starting hypothesis (Kim et al., 1994). 
It has been shown that 85%-90% of human tumors are positive for telomerase activity. 
However, the levels of telomerase activity can vary substantially and even some normal somatic 
cells have been found to have low levels of enzyme activity (Hamad et al.,2002). It has been 
investigated whether there is a minimum level of telomerase activity required for tumorigenesis. 
Using mutants of hTERT it has been shown that there is a threshold of activity required for the 
process of immortalization, transformation and tumorigenesis. Thus, low level of telomerase 
activity detected in some somatic cells would not be expected to contribute to tumorigenesis and 
nor the detection of the enzyme in cancer cells necessarily signify an immortal lifespan (Hamad 
et al.,2002). 
Telomerase Inhibition as an Anti-Cancer Treatment Strategy 
There are a number of issues to consider in attempting to develop specific anti-telomerase 
therapies directed against cancer cells (Autexier and Greider,1996; Pitts and Corey,1999). First, 
15% of immortal and tumor cells have no detectable telomerase activity.  
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Conversely, activity has been reported in some human somatic tissues (Colgin and 
Reddel,1999). This means that telomerase activity is not a restricted characteristic of tumor cells 
but can play a role in carcinogenesis along with numerous other molecular pathways. Anti-
telomerase therapy could be used also in combination with chemotherapy. Another important 
point to keep in mind is the drug resistance issue. Targeting telomerase activity carries the risk of 
inadvertently inhibiting other polymerases. The development of telomerase inhibitors that 
manifest early secondary effects may, after all, be possible (Pitts and Corey,1999; Mata and 
Iversen,1997; Kondo et al.,1998). 
Targeting the RNA Component 
In mice, deletion of the telomerase RNA component resulted in the loss of telomeres and 
end-to-end fusion of chromosomes, but only in the 4th generation of knock-out mice derived 
from the progenitor stock (Blasco and Greider,1997). Six to seven generations of mice were 
required before the mice developed abnormal phenotypes, which included defective 
spermatogenesis and decreased proliferation in testis and hematopoietic cells of the bone marrow 
and spleen (Lee et al.,1998). However, two telomerase inhibitors have been described that cause 
immediate cell death, perhaps by triggering cell cycle arrest. In yeast, deletion or mutation of the 
genes encoding telomerase RNA, catalytic or associated subunits of telomerase lead to telomere 
shortening, eventual death of most of the population and the selection of survivors able to rescue 
telomere lengths as a result of recombination based alternative telomere maintenance 
mechanisms (Colgin and Reddel,1999; Singer and Gottschling,1994; Nakamura et al.,1998).  
Hammerhead ribozymes have also been designed to cleave human telomerase RNA 
(hTR) (Kanazawa et al.,1996). Several oligonucleotides derivatives have been tested as a 
telomerase inhibitors, including DNA phosphorothioate (PS) oligonucleotides, peptide nucleic 
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acids (PNAs) and 2’-O-methyl (2’-O-me) RNAs. An interesting class of anti hTR is constituted 
by the PNAs (Corey,1997). These compounds give the highest specific in vitro inhibition of 
telomerase (Norton et al.,1996; Hamilton et al.,1997; Hamilton et al.,1999). Compared to 
standard oligonucleotides or PS oligonucleotides, PNAs bind to targeted RNA more rapidly and 
with higher affinity and specificity. By using overlapping PNA-DNA hybrids instead of 
complementary ones, the authors expected to be able to use the DNA as a carrier, then allow the 
DNA to be digested by nucleases inside the cell. The PNAs would then be free to bind its target. 
None of the PNA-DNA hybrids tested were immediately toxic and the telomerase inhibition 
persisted for three population doublings, indicating that the amount of PNA that is delivered to 
the cells is sufficient to withstand the dilution caused by segregation during cellular division. 
After a 4 week treatment, telomere shortening was observed, confirming the specificity of the 
PNA inhibitors. Conclusion: the discovery that PNAs directed against non template regions of 
the human telomerase RNA can be potent telomerase inhibitors (Hamilton et al.,1999) offers a 
new set of targets for exploration. 
Targeting the G-Quadruplex Complex 
Another approach is to target the G-quadruplex, structures that can be adopted by single 
stranded G-rich regions such as those found at the ends of chromosomes (Wellinger and 
Sen,1997). It has been speculated that such structures form at chromosome ends and that these 
structures are essential for proper telomerase function; several molecules that bind to G quartets 
have been identified to inhibit telomerase activity (Sun et al.,1997; Izbicka et al.,1999; Fedoroff 
et al.,1998). However such molecule can bind both to DNA and RNA reducing their specificity 
(Pitts and Corey,1999) and may also inhibit processes involved in immunoglobulin gene 
rearrangement and transcriptional regulation (Fedoroff et al.,1998).  
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Recently, a natural product, called telomestatin, has been isolated from Streptomyces 
anulatus 3533- SV4 and it seems to have very potent anti-telomerase properties due to the 
structural similarity with the G tetrad. This inhibitory effect might be due to the capacity to trap 
out preformed G- quadruplex structures enabling telomerase to use primer molecules required for 
its activity (Kim et al.,2002). 
Targeting the Catalytic Subunit 
Directly targeting the catalytic protein component, hTERT instead of the RNA 
component, hTR, may be more effective, as telomerase activity correlates best with the 
expression of hTERT (Nakamura et al.,1997). Human telomerase reverse transcriptase is 
expressed in all telomerase positive cells and in only a specific subset of telomerase negative 
cells that are thought to have long term proliferative capacity (Kolquist et al.,1998). However, to 
date, the only reported telomerase inhibitors that targets hTERT is the expression of a mutant 
catalytic subunit of human telomerase (Hahn et al.,1999; Zhang et al.,1999). The effects of 
inhibiting hTERT by the expression of dominant negative mutants of hTERT include the 
inhibition of telomerase activity, telomere loss, chromosome damage, apoptosis and cell death of 
various human cancer cell lines (Hahn et al.,1999; Zhang et al.,1999).  
Monoclonal antibodies (MAbs) capable of neutralizing hTRT represent a new strategy 
for use in clinical diagnosis and treatment of cancer. A recent study described the creation of an 
hybridoma M2 clone whose Mabs were specific for hTRT. In TRAP-PCR ELISA, M2 markedly 
decreased the activity of human telomerase in HeLa cells (Wang et al.,2002).  
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Telomerase Expression in Human Lymphoid Tissue 
Peripheral blood lymphocytes have low to undetectable levels of telomerase expression 
whereas early progenitor bone marrow stem cells and thymocytes express high levels of 
telomerase activity. Telomerase activity is up-regulated about 1000-fold in human B 
lymphocytes in the germinal center. This up-regulation is thought to preserve telomere length 
during the extensive cellular proliferation that occurs in the response to antigenic stimulation. 
Telomerase can be up-regulated also in vitro by activation of B cells by serum immunoglobulin 
(sIg) or cluster of differentiation 40 (CD40) signalling. Once germinal center B cells differentiate 
into memory B cells, telomerase activity is down-regulated (Hu and Insel, 1999). 
Peripheral blood mononuclear cells (PBMC) contain both lymphocytes and monocytes. 
Normal monocytes do not express telomerase activity. Thus, the low level of telomerase activity 
that has been found in PBMC from healthy donors represents telomerase expression in 
lymphocytes. Increased telomerase activity has been found both in blood lymphocytes and skin-
homing T-cell lymphocytes, even in the early stages of proliferative diseases such as 
parapsoriasis. Higher levels of telomerase activity were found in skin-homing T-cell 
lymphocytes compared with that of PBMC. One possible reason could be that telomerase activity 
reflects proliferation of the cells or, more likely, that telomerase activity is present in a subset of 
malignant or pre-malignant cells (Wu et al., 1999). In this research study, the presence of 
telomerase activity and reduced telomere length in skin-homing T-lymphocytes from patients 
with CTCL has been supported. Similar results have been achieved in blood lymphocytes, 
supporting the concept that CTCL lymphocytes, both in the blood and in the skin, are 
predestined to become malignant T-lymphocytes. 
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The induction of telomerase during the activation of T lymphocytes has recently been 
characterized. In cultured lymphocytes, telomerase activity can be induced by exposure to 
phytohemoagglutinin (PHA), interleukin 2 (IL-2), anti CD3 monoclonal antibodies (MoAb), 
calcium ionophore A23187 and phorbol esters (Kosciolek and Rowley,1998). 
Germ line cells seem to maintain a stable length of their telomeres while bone marrow 
stem cells and lymphocytes lose telomeric repeats despite telomerase activity both in vivo and in 
vitro. Germinal center (GC) B cells express high levels of telomerase activity. Significant 
telomere lengthening was observed as naive B cells matured to centroblasts and when 
centroblasts further mature to centrocytes, resulting in an increase in telomere length of about 4 
kbp as determined by Southern blotting techniques. (Norrback et al., 2001). Along with the 
telomere lengthening, telomerase activity was up-regulated to high levels in the centroblasts and 
further more in the centrocytes. These authors speculated that this could be explained by an 
accumulation of telomerase with each cell division in the centroblast population, which then 
matures into centrocytes. Non-GC cells (resting naive, activated naive and memory B cells) have 
low or undetectable telomerase activity (Norrback et al., 2001). 
Telomerase activity was detected in human lymphocytes obtained from normal donors. 
Telomerase was up-regulated within 24 hours when peripheral blood mononuclear cells were 
cultured in the presence of phytohemagglutinin. The activity increased gradually over 72 hours, 
than remained stable for 96 hours. These results demonstrate that telomerase is regulated during 
lymphocyte activation as cells progress from G0 to S phase (Yamada et al.,1996). 
In a previous work (Broccoli et al., 1995), bone marrow and peripheral blood leukocytes 
from 19 lymphocytic leukemia patients were found to express high levels of telomerase activity. 
Telomerase activity was also detected in nonleukemic bone marrow and peripheral blood 
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leukocytes from normal donors. These data indicated that human telomerase is not restricted to 
the immortal phenotype. Telomerase expression was not expected in human hematopoietic cells 
because both circulating and bone marrow leukocytes show losses of telomeric repeats over time. 
One explanation is that telomere shortening can occur despite telomerase activity. Based on this 
work (Broccoli et al.,1995) telomerase activity per se may be not directly correlated to disease in 
all malignant tumors. In another study (Norrback et al.,1996), strong telomerase activity was 
demonstrated in vivo in normal mature lymphocytes, as well as in malignant lymphoma. Benign 
lymph nodes had lower telomerase activity compared with the malignant counterpart. High-grade 
lymphomas had higher levels of telomerase activity compared with low-grade lymphoma. The 
data showed that in vivo activation of telomerase is a characteristic feature of germinal center B 
cells. Different signal for activation of telomerase are likely to exist, and one of them can be 
immune stimulation. The authors suggest an “induction and retention” model to explain 
telomerase activity in lymphomas. Based on this model, transformation occurs in a normal, 
mature B cell with reactivated telomerase, which is retained in the neoplastic clone (Norrback et 
al.,1996). High telomerase activity was also detected in non-Hodgkin’s lymphomas (Lin et al., 
2001). Enhanced telomerase activity combined with deregulation of the factors responsible for 
cell survival and proliferation may contribute to the development and progression of lymphomas 
(MacNamara et al.,2001). 
Telomerase activity was detected in skin biopsies from four cutaneous T-cell lymphoma 
(CTCL) or mycosis fungoides (MF) patients. From these biopsies, cell lines have been 
established. Both skin-homing T-cell lines and peripheral blood mononuclear cells (PBMC) from 
patients with MF had high telomerase activity and short telomere length, whereas a low level of 
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telomerase expression and normal telomere length was found in patients with lymphomatoid 
papulosis and among healthy donors (Wu et al., 1999). 
In a different study it has been investigated whether telomerase expression was useful for 
the detection of occult malignant cells in lymph nodes (Yashima et al.,1997). The TRAP assay 
was used in this research project. The results of the study indicated that 96% of the histologically 
negative nodes expressed low levels of activity that may be derived from activated lymphocytes 
that express telomerase activity. All the malignant nodes expressed telomerase. In situ results 
showed clearly that the hTR was expressed relatively highly in metastatic cancer cells and at low 
levels in germinal centres of secondary follicles. The conclusion of the work stated that although 
telomerase expression by activated lymphocytes may limit its usefulness, measurement of 
enzyme activity combined with detection of hTR using in situ hybridization may assist in the 
histopathological diagnosis of lymph nodes (Yashima et al.,1997). 
Telomerase Activity in Canine Tissues 
The canine species has been proposed as an alternative model system to study telomere 
and telomerase biology (Nasir et al.,2001). The TRAP Assay has been shown to be suitable for 
canine tissue (Biller et al.,1998).  
One of the first works that focused on the evaluation of telomerase activity in neoplastic 
tissue of dogs assessed 33 client-owned dogs with different kinds of neoplastic diseases 
diagnosed by histopathology. Oral, thoracic and abdominal masses as well as skeletal muscle and 
bone lesions were the most representative samples in this study. Twenty-four of 26 malignant 
tissues, 1 of 4 benign tumors and 0 of 3 normal tissues were telomerase positive (Biller et 
al.,1998).  
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In a different study (Yazawa et al.,1999) telomerase activity was measured using the 
TRAP assay. Normal dog somatic tissues showed little or no telomerase activity, while normal 
testis exhibited a high level of telomerase activity. Telomerase activity was measured in tumor 
samples from 45 dogs: 21 mammary gland tumors; 16 tumors of the skin and oral cavity; 7 
vascular tumors; and 1 Sertoli cell tumor. Greater than 95% of the tumor samples tested had 
detectable telomerase activity.  
The same authors, subsequently evaluated canine mammary tumors. Twenty-seven 
mammary gland tumor specimens obtained during necropsy and 12 mammary gland tissue 
specimens obtained from healthy dogs were examined for telomerase activity. Telomerase 
activity was detected in 26 of 27 mammary gland tumors and in 4 of 12 normal tissue specimens 
(Yazawa et al.,2001).  
Recently telomerase activity was evaluated in lymph nodes, buffy coat, and serum 
samples from dogs with malignant lymphoma and in liver, lymph node, buffy coat and serum 
samples from clinically normal dogs (Carioto et al.,2001). The TRAP assay was the method 
utilized in this experiment. Of 11 clinically normal dogs, 8 had lymph node samples, 5 had liver 
samples and 1 had buffy coat samples with detectable telomerase activity. None of the serum 
samples from the clinically normal dogs had detectable telomerase activity. Of 14 dogs with 
lymphoma, 9 had lymph node samples, 3 had buffy coat samples, and 1 had serum samples with 
measurable telomerase activity. These authors concluded that telomerase activity was not 
specific for tumor cells in the dog. There was no difference in telomerase activity in lymph nodes 
of clinically normal dogs and dogs with lymphoma. 
The presence or absence of telomerase activity in canine and feline body cavity effusions 
was compared with the cytologic evaluation (Spangler et al., 2000). Detection of telomerase in 
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effusions was no more sensitive than cytologic evaluation for the identification of neoplasia. In 
this study cytologic evaluation was more specific than the TRAP assay (telomerase assay: 
sensitivity = 50%, specificity = 83%; cytology: sensitivity = 50%, specificity = 100%). The 
conclusion of this work pointed out the telomerase assay may constitute a useful adjunctive test 
for the diagnosis of neoplastic disease in dogs and cats with body cavity effusions. However, the 
results of this assay are not sufficiently reliable to be used as a sole diagnostic test (Spangler et 
al., 2000). 
Another study hypothesized that telomerase activity was present in both normal and 
lymphoma lymph nodes and that neoplastic tissue had higher level of telomerase activity (Hipple 
et al.,2001). Statistical analysis found no difference in telomerase activity between normal and 
lymphoma lymph nodes. This study concluded stating that telomerase activity was not predictive 
of survival or remission duration in dogs with lymphoma. 
Lymphoma in the Dog 
Epidemiology 
Lymphoma is a neoplasm of malignant lymphocytes. Lymphoma arises from a clonal 
expansion of lymphoid cells with distinctive morphologic and immunophenotypic features. 
Lymphoma is one of the most common malignant tumors in the dog and it is the most common 
hematopoietic tumor in this species. Seven to 24% of all canine neoplasias are lymphomas.  
Lymphoma comprises 83% of all hematopoietic tumors in dogs. Middle-aged to older dogs (6-9 
years) are primarily affected (Withrow and MacEwen, 2001). Breed predisposition has been 
reported for boxers, Scottish terriers, basset hounds, Airedale terriers, chow-chow, German 
shepherds, poodles, St. Bernards, English bulldogs, beagles, and golden retrievers (Keller et al., 
1993). 
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Clinical Presentation 
The typical anatomic sites for canine lymphoma are multicentric, alimentary, mediastinal 
(thymic) and extranodal (renal, CNS, skin, eyes). The multicentric form is the most common 
accounting for up to 84% of all cases. Alimentary lymphoma is the second most common (7%) 
anatomic form followed by the extranodal form (< 7%) and the mediastinal form (< 2%) 
(Morrison WB,1998). 
Multicentric Lymphoma 
Multicentric lymphoma involves multiple lymph nodes and may also extend to liver, 
spleen, and bone marrow (BM). Dogs with multicentric lymphoma are usually middle-aged and 
are presented for painless, recently noticed lymphadenopathy. Nonspecific clinical signs include 
weakness, lethargy, vomiting and weight loss. Ten to 20% of dogs with multicentric lymphoma 
have hypercalcemia of malignancy (Morrison WB., 1998). Approximately 60% to 75% of dogs 
with multicentric lymphoma have abnormalities on thoracic radiographs including interstitial 
pulmonary infiltrates and thoracic lymphadenomegaly. Abdominal radiographs display evidence 
of sublumbar lymph nodes, spleen or liver involvement in 50% of cases (Starrak et al.,1997; 
Blackwood et al.,1997). 
Alimentary Lymphoma 
Alimentary lymphoma may be characterized by a single mass or may have a diffuse 
intestinal involvement. Clinical signs associated with the alimentary form of lymphoma include 
weight loss, vomiting, diarrhea, anorexia, malabsorption and melena. 
Mediastinal Lymphoma 
The mediastinal form involves the cranial mediastinal lymph nodes or the thymus. 
Dyspnea, coughing, regurgitation, exercise intolerance and dysphagia are clinical signs 
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associated with mediastinal lymphoma. Compression of the vena cava can cause cervical and 
facial edema. Up to 40% of dogs with mediastinal lymphoma present with hypercalcemia 
(Morrison WB., 1998). Pleural effusion may be seen. The mediastinal form of lymphoma in dogs 
is most commonly associated with a T-cell phenotype (Ruslander et al.,1997). 
Extranodal Lymphoma 
Extranodal lymphoma involves all non-lymphoid organ sites, such as central nervous 
system (CNS), skin, kidney, eyes and heart. Clinical signs associated with the extranodal form 
may be nonspecific (anorexia, weight loss, lethargy, PU/PD) or specific depending on the organ 
involved. Lymph nodes involvement may be or may be not present. 
Clinical Pathology 
Laboratory abnormalities, seen in dogs with lymphoma, include anemia (38% of cases), 
thrombocytopenia (58% of cases) caused by bone marrow invasion or immune complications 
(Madewell BR,1986), or hypercalcemia (10-40% of cases) secondary to the production of a 
parathyroid hormone-related peptide (PTHrP) (Teske E, 1994). Specific organ involvement may 
be reflected in lab work. 
WHO Staging of Lymphoma 
Canine lymphoma is clinically staged in five categories according to the involvement of 
specific anatomic compartments or organs (Table 5). Each of the five stages may include two 
different sub-stages. Substage A is considered any stage without systemic signs of disease 
whereas substage B is considered any stage with systemic signs of disease. 
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Diagnosis 
Several examinations are available to help the clinician in the diagnostic process of 
lymphoma. A complete physical examination, hematologic panel, serum biochemistry panel, fine 
needle aspiration (FNA), radiographic and ultrasonographic imaging, histopathology and 
ophthalmologic examination should be performed. While cytology provides a diagnosis of 
lymphoma, a tissue biopsy should be performed to confirm the diagnosis and to histologically 
grade the tumor. Immunophenotyping by immunohistochemistry or immunocytochemistry is 
becoming more available to veterinary clinicians (Carter RF and Valli VEO., 1988). Thoracic 
radiography may reveal abnormalities including enlargement of the retrosternal or 
tracheobronchial lymph nodes, pulmonary infiltrates, mediastinal masses, and pleural effusion. 
Abdominal radiographs may show alteration in organ size and structure. Laboratory examination 
may reveal hematological and serum abnormalities such as anemia, thrombocytopenia, 
leukopenia and hypercalcemia. Peripheral blood smears, bone marrow aspirate and bone marrow 
core biopsy may be helpful in the staging process. 
Prognostic Factors 
Several prognostic factors have been established for canine lymphoma. Negative factors 
include high stage (stage V), substage B, hypercalcemia, mediastinal lymph node involvement, 
T-cell phenotype, lack of response to chemotherapy, histopathological grade and p-glycoprotein 
expression (Morrison WB.,1998). 
 Treatment and Prognosis 
The therapeutic approach to a patient with lymphoma is determined by the stage or 
substage of disease, the presence of paraneoplastic syndromes, intercurrent disease status, and 
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financial concerns of the client. Without treatment, most dogs die within 4 to 6 weeks of 
diagnosis (Withrow and MacEwen., 2001). Lymphoma is a very responsive tumor to 
chemotherapy. Conventional chemotherapy results in approximately 60% to 90% of dogs 
achieving complete response (CR), with median survival duration of 6 to 12 months, depending 
upon the chemotherapy protocol employed (Withrow and MacEwen., 2001). Noticeable 
remission may begin within a few hours of drug administration, but typically occurs within the 
first week of treatment. Most first remissions last 6-8 months. Second and subsequent remissions 
are increasingly more difficult to obtain and are of briefer duration than first remission. Overall 
survival time for dogs with lymphoma is generally 9-12 months. The primary goal of 
chemotherapy is to induce a complete and durable remission, then to re-induce or rescue a 
remission after one or more relapses. Most relapses are due to inadequate dosing and frequency 
of administration, development of multidrug resistance (MDR) following exposure to selected 
chemotherapeutic drugs (Kartner et al.,1983; Bergman et al.,1996) and failure to achieve 
sufficient concentrations of drugs in specific privileged anatomic locations such as the brain.  
There are many chemotherapeutic protocols available to treat lymphoma in dogs. Single 
agent chemotherapy or multidrug protocols are chosen according to individual case and factors.  
Single agent therapy is not considered the standard therapy for canine lymphoma. 
However it represents the simplest and cheapest option. With corticosteroids most dogs attain a 
short remission and improve quality of life. Median survival time for dogs treated with steriods 
alone is 53 days compared with untreated dogs that live 30 days on average. It has been shown 
that steroids therapy can induce the phenomenon of drug resistance by overexpressing p-
glycoprotein, a cell membrane pump required for removal of drugs from cells. 
Cyclophosphamide is an alkylating agent commonly used in the treatment of lymphoma. Dogs 
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treated with cyclophosphamide alone can achieve a longer remission duration (median 165 days) 
compared with prednisone. Shorter remission duration have been noted for chlorambucil alone or 
even in combination with prednisone compared with cyclophosphamide. Chlorambucil is used as 
a substitute for cyclophosphamide in the case of sterile hemorrhagic cystitis. Most dogs show a 
partial response rate to L-asparaginase single agent. Vincristine and vinblastine can produce a 
short remission time when used alone (30-180 days). Around 56% of dogs with lymphoma 
treated with single agent doxorubicin obtained a complete or partial remission. The median 
duration of the first remission was 38 days and median survival time was 100 days. This drug has 
the potential for considerable side effects including anaphylaxis, perivascular sloughing, 
myelosuppression, gastrointestinal and cardiac toxicities. Epirubicin is used as a substitute of 
doxorubicin. Mitoxantrone is a minimally cardiotoxic analog of doxorubicin. Actinomycin D is 
another anti-tumor antibiotic used in the treatment of lymphoma. Lomustine (CCNU) is an 
alkylating agent that has been used as a rescue agent for refractory multicentric lymphoma 
(Morrison,1998). 
Most of multi-drug protocols have induction and maintenance phase. Many of the 
protocols used in dogs are based on the combination of cyclophosphamide, vincristine and 
prednisone, with or without doxorubicin. The COP protocol consist of cyclophosphamide, 
vincristine and prednisone given for 6 weeks of induction, followed by a maintenance protocol 
of methotrexate, higher dose cyclophosphamide, and lower dose prednisone for an additional 6 
weeks. Complete remission and partial remission were achieved in 69% of the dogs. Median 
survival time was 123 days. The CHOP protocol contains the same drugs contained in the COP 
plus doxorubicin. Median survival time for this protocol is about one year. The University of 
Wisconsin-Madison protocol (vincristine, L-asparaginase, cyclophosphamide, prednisone and 
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doxorubicin) is reported to have one of the longest remission (252 days) and survival time (357 
days). A different protocol is known as COPLA (induction phase with cyclophosphamide, 
vincristine, prednisone, L-asparaginase and doxorubicin, and maintenance phase with vincristine 
and chlorambucil). Remission and survival times are the same as most combination protocols, 
but the number of dogs achieving remission is high and the protocol is well-tolerated 
(Morrison,1998). The most common protocols for refractory lymphoma are those including 
doxorubicin/dacarbazine combination and the MOPP protocol (methclorethamine, vincristine, 
procarbazine, and prednisone). Usually a 40% to 50% response rate is achieved (Withrow,2001). 
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CHAPTER 3. TELOMERASE ACTIVITY IN CANINE 
LYMPHOCYTES 
Objectives 
Based on the hypothesis that telomerase is a specific marker for neoplastic tissues, the 
development of methods to detect its activity may represent an accurate, non-invasive diagnostic 
and prognostic tool for use in clinical veterinary medicine. The aim of this study was to detect 
telomerase activity in normal, hyperplastic and neoplastic lymphocytes comparing two different 
detection methods: the TRAP assay and the TRAP ELISA Telomerase Detection Kit. These tests 
are commercially available and commonly used to detect telomerase activity. The TRAP assay is 
a PCR based protocol that relies on detecting a ladder of fragments after electrophoresis of a 
polyacrylamide gel. The TRAP ELISA utilizes a colorimetric detection method, omitting the gel 
preparation step. The TRAP ELISA seems to be easier and less time consuming to perform. This 
study was undertaken to establish the relative sensitivity and specificity of these methods in 
canine lymphoid tissues. 
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CHAPTER 4. MATERIALS AND METHODS 
Study Population 
The study population consisted of client-owned dogs that underwent surgical biopsy or 
exploratory procedure during their hospitalization at the University of Illinois – Veterinary 
Teaching Hospital (VTH). Tissue sample in excess of that required for clinical diagnosis were 
collected from the operating room. Informed consent was given by the owner for collection of 
part of the samples used for this study. This study population included dogs with neoplastic or 
non-neoplastic conditions and all dogs with neoplastic diseases had a diagnosis of lymphoma. 
Normal lymph nodes samples were harvested from control research dogs euthanized as part of 
other research studies. 
Sample Collection and Storage 
Resected tissue was submitted for diagnostic histopathology analysis in  formaldehyde 
preservative to a board certified veterinary pathologist at the University of Illinois Veterinary 
Diagnostic Laboratory. At surgical biopsy, part of each sample was rapidly frozen in liquid 
nitrogen, then stored at -80°C until used for the molecular procedures described herein.  
Telomerase Extract Preparation 
Tissue extracts were obtained from frozen samples by mincing 40-100 mg of tissue with 
a sterile scalpel blade. Samples were transferred to a sterile 1.5 ml microcentrifuge tube and 200 
μl of 1X ice-cold CHAPS lysis buffer [10 mM tris-HCl (pH 7.5), 1 mM MgCl2, 1 mM EGTA, 
0.1 mM Benzamidine, 5 mM β-mercaptoethanol, 0.5% CHAPS and 10% Glycerol] was added. 
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At this point, homogenization with a motorized pestle was performed until a uniform consistency 
was achieved (~ 10 seconds). After, that the suspension was incubated on ice for 30 minutes, 
centrifuged at 12,000 x g for 20 minutes at 4˚C. Each supernatant (approximate volume 160 μl) 
was transferred into a fresh tube and stored at - 80˚C. Protein concentration was determined for 
each extract using the Coomassie protein assay reagents1. 
TRAP Assay 
Principle and Methodology of the Assay 
In this experiment, the Intergen's TRAPeze® Telomerase Detection Kit was used. This 
kit is based on an improved version of the original method described by Kim, et al, which is 
more accurate and rapid to perform. The kit is a highly sensitive in vitro assay for detecting 
telomerase activity. In the first step of the reaction, telomerase adds a number of telomeric 
repeats (GGTTAG) onto the 3' end of a substrate oligonucleotide (called the TS primer). In the 
second step, the extended products are amplified by PCR using the TS and RP (reverse) primers 
to generate a ladder of products in 6 base pair increments starting at 50 nucleotides. This product 
is visualized on a 12%  polyacrylamide gel. 
Experimental Control Included in Each Assay 
Heat inactivation control. Because telomerase is a heat sensitive ribonucleoprotein 
enzyme, every sample extract should also be tested for heat sensitivity as a negative control. 
Thus, analysis of each sample consists of two assays: one with a test extract and one with a heat-
treated test extract. Heat inactivation was achieved by incubating the sample at 85˚C for 15 
minutes prior to the TRAPeze kit amplification. 
                                                 
1 Pierce, Rockford, IL. 
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Telomerase positive control. The TRAPeze Kit includes a known telomerase positive cell 
pellet. An extract was made from the pellet as described for tissue extracts and included as a 
positive standard control in each TRAP assay. In addition we included a cell pellet created in our 
laboratory from a known telomerase positive canine osteosarcoma line. 
PCR amplification control. Two internal control oligonucleotides called K1 and TSK1 
were included in each reaction mixture. When paired with the TS primer, provided in the kit, 
they produce a 36 base pair (bp) band (S-IC) in every lane on the gel. Visualization of this band 
allows verification of PCR amplification and elimination of false-negative results. False negative 
can result from the presence of inhibitors of Taq polymerase sometimes contained in the cell or 
tissue extracts. 
Primer-dimer/PCR contamination control. Non-specific primer annealing produce PCR 
artifacts that occur by introduction of primers alone without appropriate template DNA. This 
binding pattern represents a negative control for the assay. 
TSR8 quantitation control. TSR8 is an oligonucleotide with a sequence identical to the 
TS primer but extended by 8 telomeric repeat hexanucleotide sequences, AG(GGTTAG)7. When 
TSR8 is included as the template DNA rather than the sample extract this serves as a second 
positive control and as a standard for estimating the amount of TS primers extended by 
telomerase in a given sample extract. 
TRAP Assay Reactions 
One μl of each extract was added to 24 μl of the Master mix for a total volume of 25 μl. 
The tubes were then placed in the thermocycler block and incubate at 30ºC for 30 minutes. We 
used a modified version of the PCR program provided with the kit because prior work in our 
laboratory allowed us to optimize the assay for use in canine tissues. 
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Cycle conditions consisted of a melting phase, an annealing phase and a final extension-
amplification phase. 
94ºC x 30'' 
50ºC x 30''         x 30 
72ºC x 30'' 
70ºC x 10' 
Gel Electrophoresis 
Five μl of gel loading dye containing bromophenol blue and xylene cyanol was added to 
each sample tube after PCR amplification. Approximately 28 μl of each sample was loaded into 
appropriate lanes of a 12% non-denaturing polyacrylamide gel. To prevent contamination 
between samples in adjacent gel lanes, alternate lanes were loaded. The gel was run in 1X Tris-
Boric acid-EDTA buffer (TBE) in a vertical gel box for 3 hours at 34 mA. 
Visualization 
After electrophoresis, the gel was stained with SYBER Green2 diluted approximately 
1:10,000 in 1X TBE. The gel was than shaken gently on a rocker platform for at least 15 minutes 
in the stain solution. An ultra-violet light box was used for band detection. Results were captured 
with a Polaroid camera system. 
TRAP-ELISA Assay 
Principle and Methodology of the Assay 
In this experiment, Intergen’s TRAPeze® ELISA Telomerase detection kit was used. The 
TRAP-ELISA method is based on an alteration of the original assay described by Kim et al. The 
kit includes reagents for non-radioactive detection of the telomerase products by an ELISA 
                                                 
2 Roche, Indianapolis, IN. 
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protocol. The procedures are separated into two steps: TRAP extension/amplification and 
detection. In the first step of the reaction, telomerase adds a number of telomeric repeats 
(GGTTAG) onto the 3’ end of a biotinylated Telomerase Substrate oligonucleotide (b-TS). In the 
second step, the extended products are amplified by the polymerase chain reaction (PCR) using 
Taq polymerase, the b-TS primer and RP (reverse) primers, and a deoxynucleotide mix 
containing dCTP labeled with dinitrophenyl (DNP). This extension/amplification reaction 
generates a ladder of products with 6 base increments starting at 50 nucleotides. Thus, the TRAP 
products are tagged with biotin and DNP residues. The labeled products are immobilized onto 
streptavidin-coated microtiter plates via biotin-streptavidin interaction and then detected by anti-
DNP antibody conjugated to horseradish peroxidase (HRP). The amount of TRAP product is 
estimated by means of the HRP activity using a colorimetric substrate 3,3’,5,5’- 
tetramethylbenzidine (TMB). While the method is not-completely quantitative, telomerase 
activity in extracts made from 30-1,000 telomerase positive cells can readily be measured. 
Telomerase activity from as few as 30 telomerase positive cells among 3,000 negative cells can 
be detected with the TRAPeze® ELISA. 
The experimental controls included in this assay were the same used for the TRAP assay 
procedure. 
TRAP ELISA Assay Reactions 
Two μl of each extract were added to 48 μl of the Master mix for a total volume of 50 μl. 
The tubes were then placed in the thermocycler block and incubate at 30ºC for 30 minutes. We 
used a modified version of the PCR program provided with the kit, because prior work in our 
laboratory allowed us to optimize the assay for use in canine tissues: 94°C/30 sec., 55°C/30 sec. 
for 33 cycles. 
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ELISA Detection 
Pretreatment of the microtiter plate (MPT) consisted of the addition of 250 μl of 
blocking/dilution buffer into each well, incubation at 37°C for 30 minutes, removal of the 
blocking buffer and rinsing with 1X washing buffer. Subsequently, 100 μl of the blocking buffer 
were added to each well along with 5 μl of the TRAP reaction product created. After 1 hour 
incubation at 37°C, the solution was removed and wells rinsed 5 times with 1X washing buffer. 
In the meantime, the stock antibody solution was diluted 1:250 with blocking buffer and 100 μl 
of anti-DNP antibody-HRP conjugate were added to each well. After 30 minutes incubation at 
room temperature the antibody solution was removed and wells rinsed 5 times with 1X washing 
buffer. Subsequently, 100 μl of TMB solution were added to each well and the mix was 
incubated for 10 minutes at room temperature. Finally, 100 μl of stop solution were added to 
each well. This last reaction causes color change of the peroxidase product from blue to yellow. 
The absorbance of the samples was measured at 450 and 630 nm. 
Data Analysis 
In order for the TRAP ELISA assay to be valid, the controls must have the following 
absorbance measurements: primer/dimer/PCR contamination control should have a value of 
absorbance (A) < 0.200; TSR8 PCR/ELISA control should have a value > 0.800; heat inactivated 
sample extract should have a value < 0.250; experimental samples should have a value ΔA> 
0.150 to be positive (ΔA=Asample – Aheat treated sample).  
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CHAPTER 5. RESULTS 
TRAP Assay Results 
The TRAP Assay was used to examine neoplastic and reactive lymphoid tissues of client-
owned dogs. Normal node tissues were obtained from control dogs euthanized at the conclusion 
of unrelated projects. Fifteen lymphomatous tissue samples, 13 normal lymph nodes and 2 
reactive lymph nodes were available for the study. Telomerase positive samples were 
characterized by a relatively intense band at 50 base pairs with a ladder of incrementing bands at 
intervals of 6 base pairs. The comparator for this study was the histopathological examination. 
Based on this method we obtained a very strong correlation between the histopathologic 
diagnosis and the telomerase outcome. Of 15 histopathologic diagnosed lymphomas, 12 were 
telomerase positive (80%) and 3 were telomerase negative (20%). Of 15 non-lymphomatous 
nodes, including normal and reactive nodes, 14 were telomerase negative (93%) and only one 
was telomerase positive (6.7%). Both of the two reactive lymph nodes were telomerase negative. 
Analysis of these results indicates a sensitivity of 80% and specificity of 93% for this method 
(Table 7). 
TRAP ELISA Results 
This method was used simultaneously using the same samples tested by the TRAP assay.  
Of 15 lymphoma samples tested, 11 were positive (73%) whereas 4 were negative (27%). Of 15 
non-lymphomatous nodes, including normal and reactive nodes, histologically normal lymph 
nodes, 2 were telomerase positive (15%), whereas 13 were negative (85%). Both of the two 
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reactive lymph nodes were telomerase negative. Analysis of these results indicates a sensitivity 
of 73% and specificity of 87% for this method (Table 8-9).  
Statistical Analysis 
Sensitivity, Specificity and Beta Distributions for TRAP Assay (Table 7, Fig. 1-2): 
Sensitivity = a/a+c = 12/(12+3) = 80% 
Specificity = d/b+d = 14/(1+14) = 93%                                    
Sensitivity, Specificity and Beta Distributions for TRAP ELISA (Table 8, Fig 3-
4): 
Sensitivity = 73% 
Specificity = 86% 
Diagnostic Odds= 17.8 
 
 In summary, we can say that estimates of sensitivity and specificity inherently are 
uncertain and the estimate of potential error is measured by the β-distribution of the sample 
population. When the TRAP ELISA test is applied to a specific dog we cannot know which is the 
actual value of sensitivity and specificity, but we know that all the possible values are those 
described by the β-distribution (Table 10-11). By means of the simulation, we have virtually 
applied the test to a sample of 1000 dogs with an 80% probability that the dog in question has 
lymphoma. Analysis of 1000 virtual samples allows the simulation to calculate the final 
probability value for a dog to have a tumor after a positive outcome on the TRAP ELISA. The 
computer obtained this result by combining all the possible values of sensitivity and specificity 
described by the β-distribution. The computer also considered the probability associated with the 
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single value, that is, the probability that a given different value can be registered. This analysis 
states that if we obtain a positive result using 1000 dogs for the TRAP ELISA: 25% of dogs will 
have a probability to truly bear a tumor ranging from 80% and 92%; 25% of the dogs will range 
between 92% and 94%; 25% will range between 94% and 96% and the last 25% will range 
between 96% and 100%. Based on this we can state that the TRAP ELISA is truly predictive of 
the dog’s disease status.  
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CHAPTER 6. DISCUSSION 
In this study the TRAP and the TRAP ELISA assay have been used to detect telomerase 
activity in normal and neoplastic canine lymph nodes. Our results indicate a strong correlation 
between telomerase activity and presence of lymphoma in the animal by using both of these two 
methods. |Compared to the conventional TRAP assay, the TRAP ELISA is less time consuming 
because neither gel preparation nor electrophoretic separation steps are required. Telomerase 
activity from as few as 30 telomerase positive cells among 3,000 negative cells can be detected 
with the TRAPeze® ELISA. 
While the manufacturer describes the TRAP ELISA assay to be more sensitive and 
specific than the TRAP assay, we found that the TRAP assay was more sensitive in this 
application.  
The value of detecting telomerase activity is that this activity has potential clinical 
application as a diagnostic, prognostic and therapeutic tool. However, it is important to 
understand that while 90% of human tumors are positive for telomerase activity, the level of 
activity can vary substantially. Also, selected normal somatic cells have been found to have low 
levels of enzyme activity (Hamad et al., 2002). Thus, low levels of telomerase activity detected 
in some somatic cells should not be considered an indication for  tumorigenic potential and nor 
should the detection of the enzyme in neoplastic cells necessarily signify an immortal phenotype 
(Hamad et al., 2002). 
In the case of lymphatic tissues, human peripheral blood lymphocytes have low to 
undetectable levels of telomerase activity (Hu and Insel, 1999) whereas bone marrow progenitor 
stem cells and thymocytes express high levels of enzyme activity. Different studies indicate 
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increased telomerase activity in both blood lymphocytes and skin-homing T-cell lymphocytes 
(Wu et al., 1999). In germinal center B lymphocytes, telomerase expression is up-regulated 
about 1000-fold as compared to cells not located within the germinal center. Significant 
telomerase up-regulation was observed to occur as naïve B cells matured to centroblasts and 
further in centrocytes. This up-regulation is thought to be required for preserving telomere length 
during the extensive clonal cellular proliferation that follows antigenic stimulation. Once 
germinal center B lymphocytes differentiate into memory B cells, telomerase activity is down-
regulated. These studies indicate the importance of cellular developmental and replicative status 
to the interpretation of telomerase activity. Based on these and other results, telomerase activity 
per se may be not directly correlated to malignancy in all situations (Broccoli et al., 1995). 
An important advance to improve interpretation of telomerase activity as a predictor of 
patient status is quantitation of the enzyme activity. Most of the methods commonly used to 
detect telomerase activity are not quantitative. The TRAP and the TRAP ELISA assays cannot 
quantify the actual level of telomerase within the examined samples, due to the variability 
inherent in PCR amplification method. This limitation is much more important when examining 
lymphoid tissue because telomerase may be present in the malignant and in the benign cells of a 
tissue, but expressed at different levels. A key goal is to determine a "threshold" in terms of 
quantitation, to differentiate physiologic from pathologic telomerase expression. 
Assessment of the banding pattern created by using the TRAP assay requires some level 
of subjective interpretation. The band pattern may not be clear, leading to misinterpretation of 
samples with low levels of activity as false negative results. False positive results are much less 
likely with the TRAP assay. The TRAP ELISA detection method allows less subjectivity in 
interpretation because specific absorbance ranges must be detected in order for a sample to be 
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declared positive. Perhaps the best way to eliminate subjective interpretations would be to use 
one of the newly described quantitative methods such as the new ELIPA and RTQ-TRAP assay. 
The precise quantitation of telomerase activity could provide the clinician with more accurate 
information than the current “positive” and “negative” results generated with both the TRAP and 
the TRAP ELISA assays. 
Potential reasons for false negative telomerase results in histologically diagnosed 
lymphoma, include RNA degradation during sample collection, storage or processing. Because 
of the fragility of the RNA component of this ribonucleoprotein molecule, it is very important 
that the investigator be accurate and sterile in all the steps of the procedure. Sample proper 
storage conditions are also essential. Detection of amplification of the K1 and TSK1 control 
primers helps eliminate false negative results caused by Taq polymerase inhibitor substances 
present during PCR amplification. These control primers do not control for inactivation of the 
telomerase enzyme itself, however, false negative results may be seen because samples with low 
levels of telomerase activity may be below the limits of detection for the assay utilized. It is also 
important to mention that true telomerase negative tumors have been reported. A possible 
explanation for this phenomenon could be that telomerase may require a certain period of time 
(population doubling “lag”) before being activated in neoplastic cells. The period of time 
required for activation of the enzyme may be strictly related to original telomere length of the 
affected cells. Based on this concept, tumors with long telomeres might not require telomerase 
activation, or might recruit up-regulation or down-regulation of other specific genes to gain 
immortality and endless proliferative capacity. 
Telomerase positive results from normal lymph node samples represent another concern 
to be considered when using the assay as a diagnostic test for lymphoma. Normal germinal 
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center B lymphocytes have been shown to express telomerase activity after antigenic stimulation. 
Based on this phenomenon, samples from normal lymph nodes containing many germinal 
centers have a greater probability of being detected to express telomerase activity without any 
correlation to neoplasia. Because germinal center B cells are typically telomerase positive, we 
expected samples from reactive nodes to be positive. However, only two reactive nodes were 
available for this study and both were considered to be telomerase negative. Obviously this 
represented too small a sample size to make any meaningful conclusions regarding telomerase 
activity in reactive lymph nodes. Another concern to be considered when dealing with potential 
telomerase false positive results is the potential for PCR contamination with telomerase enzyme 
from sources other than the tissue being tested. 
In veterinary medicine, there is controversy among the different studies conducted to 
determine telomerase activity in normal and neoplastic tissues. A strong correlation between 
telomerase expression and malignancy was reported by several investigators (Biller et al., 1998; 
Yazawa et al., 1999; Yazawa et al., 2001). According to Carioto’s work (Carioto et al., 2001) 
telomerase activity is not specific for tumor cells in dogs with lymphoma. Detectable telomerase 
activity was found in lymph node samples from clinical normal and from lymphoma-bearing 
dogs. This lack of discrimination was also observed in Hipple’s study (Hipple et al., 2001). 
A clarifying step to better resolve this controversy would be to establish which histologic 
aspect of the normal lymph node was submitted for telomerase examination. By knowing 
whether or not the examined samples contains germinal centers, it would be possible to better 
interpret a positive or negative test result. Based on the study reported from human medicine, 
this quality assurance step aids in resolving this problem. In all telomerase studies reported in 
veterinary medicine, including those conducted in our laboratory, this clarifying step has not 
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been done. This omission leaves a source of uncertainty that could be resolved in future 
investigation. Another issue to consider is that we did not classify our samples according to the 
anatomical site from which the lymph node was harvested. Theoretically, mesenteric and 
peripheral lymph nodes could present different expression of telomerase activity based on the 
different levels of antigenic stimulation to which they are subjected. Knowing the histologic 
grade of the disease could prove very helpful in interpreting telomerase results as well. Negative 
results from histologically confirmed low-grade lymphoma could be explained by assuming that 
telomeres in cell of this type of disease are not subject to as much erosion due to cell replication 
as seen in high grade disease. Alternately, low-grade lymphoma may have cells with telomeres 
long enough to prevent telomerase activation. In our study, two of our lymphoma samples were 
negative for telomerase expression by both procedures. The histopathological assessment of 
these samples reported that one samples was diagnosed as low-grade lymphoma (sample # 10) 
and the other sample was “suspicious of lymphoma” (sample # 15) (Table 6).  
In the present study we found a strong correlation between telomerase expression and the 
biological status of the animal with regard to malignancy. One of the greatest weakness in all 
reported veterinary studies, including our own, is the lack of statistically significant sample size 
evaluated in most reports. We attempted to partially overcome this limitation by utilizing the 
Monte Carlo simulation method. With this simulation, we assessed 1000 “virtual” dogs with an 
80% pre-test probability of having lymphoma. These virtual dogs were assessed for telomerase 
activity using the sensitivity and specificity parameters determined by the TRAP ELISA assay 
conducted here. This allowed us to obtain a more precise estimate of the probability for the 
sample examined to really bear a lymphoma based on all the possible values of sensitivity and 
specificity determined by the beta-distribution for the samples tested in this work. 
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In conclusion, based on our study, we conclude that the TRAP assay is more reliable in 
term of sensitivity when compared with the TRAP ELISA. Telomerase analysis may be 
potentially useful in veterinary medicine as a diagnostic and prognostic tool for animals with 
lymphatic disease. Obviously we do not recommend utilizing the TRAP as the sole single 
diagnostic method because there remains some concern about the subjectivity of the procedure 
and the veracity of some of the positive and negative  results. Our recommendation is to use 
telomerase analysis as a further confirmation after clinical, cytological and histopathological 
analysis. 
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CHAPTER 7. TABLES 
 
 
Table 1. Telomeric Repeat Sequences in Eukaryotes 
 
Group Organism Telomeric repeat (5’ to 3’) 
Vertebrates Human, Mouse, Xenopus TTAGGG 
Filamentous fungi Neurospora TTAGGG 
Slime molds Physarum, Didymium, 
Dyctiostelum 
TTAGGG 
AG (1-8) 
Kinetoplastic protozoa Trypanosoma, Glaucoma 
Paramecium 
Oxytricha, Stylonychia, 
Euplotes 
TTGGGG 
TTGGG (T/G) 
TTTTGGGG 
Sporozoite protozoa Plasmodium TTAGGG (T/C) 
Higher plants Arabidopsis TTTAGGG 
Insects Bombyx mori TTAGG 
Nematodes Ascaris lumbricoides TTAGGC 
Alga Chlamydomonas TTTTAGGG 
Fission yeasts Schizosaccharomyces 
pombe 
TTAC (A) (C) G (1-8) 
Budding yeasts Saccharomyces cerevisiae TGTGGGTGTGGTG (from 
RNA template) 
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Table 2. The molecular cascade involved in the M1 phase entrance. 
 
 
 
 
 
 
 
 
 
 
 
Chromosome without telomeric subunits 
 
 
P53 and p21 activation 
 
 
Inhibition by p21 of cdks that are thus unable to 
phosphorylate pRb 
 
Non-phosphorylated pRb along with other actions of p53 
and p21 
 
     M1 entrance
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Table 3: Summary of TRAP Assay results for canine lymphoid tissue samples 
 
Sample Category # Tested # Telomerase 
Positive (%) 
# Telomerase 
negative (%) 
Lymphoma 15 80.0% 20.0% 
Normal 15 6.7% 93.3% 
 
 
Table 4: Summary of TRAP ELISA Assay results for canine lymphoid tissue samples 
 
Sample Category # Tested # Telomerase Positive 
(%) 
# Telomerase negative 
(%) 
Lymphoma 15 73.0% 27.0% 
Normal 15 13.3% 86.7% 
 
 
 
 
 
Table 5. Clinical staging for canine lymphoma 
 
Stage  
I Involvement of a single lymph 
node or lymphoid tissue in a 
single organ 
II Involvement of regional lymph 
nodes with or without extra-
nodal site 
III Generalized lymphadenopathy 
IV Liver and/or spleen 
involvement with or without 
stage I to III 
V Involvement of BM, kidney, 
CNS, eyes, heart with or 
without stage I to IV 
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Table 6. Samples assessed in the current study. 
 
 
Normal lymphnodes TRAP TRAP ELISA Histopathologic 
characteristic 
1) (-) (-)  
2) (-) (-)  
3) (-) (-)  
4) (-) (-)  
5) (-) (-)  
6) (-) (-)  
7) (-) (-)  
8) (-) (-)  
9) (-) (+)  
10) (-) (-)  
11) (+) (-)  
12) (-) (-)  
13) (-) (+)  
    
Lymphomas    
1) (+) (+) lymphoblastic 
2) (+) (+)  
3) (+) (+) lymphoblastic 
4) (+) (+) Intermediate grade
5) (+) (-)  
6) (+) (-) lymphoblastic 
7) (+) (+) High grade 
8) (+) (+) Intermediate grade
9) (+) (+) Diffuse large cell 
10) (-) (-) Low grade 
11) (+) (+) Large cell 
12) (-) (+)  
13) (+) (+) B-cell 
14) (+) (+) T-cell 
15) (-) (-) Suspicious of 
lymphoma 
    
Reactive Nodes    
1)  (-) (-)  
2)  (-) (-)  
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Table 7. Sensitivity and specificity results for the TRAP assay 
 
 
 
   Histopathology 
   Lymphoma Non-
lymphoma 
 
Total 
  Positive Negative  
 
Positive 
 
 
 
12 (a) 
 
1  (b) 
 
13 (a+b) 
 
TRAP 
 
Negative 
 
 
 
3 (c) 
 
14 (d) 
 
17 (c+d) 
Total 15 (a+c) 15 (b+d) 30 (a+b+c+d) 
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Table 8. Sensitivity and specificity for the TRAP ELISA results 
  Histopathology 
  Lymphoma Non-
lymphoma 
 
Total 
  Positive Negative  
 
Positive 
 
 
 
11 (a) 
 
2  (b) 
 
13 (a+b) 
 
 TRAP 
 ELISA 
 
Negative 
 
 
 
4 (c) 
 
13 (d) 
 
17 (c+d) 
Total 15 (a+c) 15 (b+d) 30 (a+b+c+d)
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Table 9. Cohen agreement coefficient for the TRAP and TRAP ELISA test. 
Observed agreement between the two tests = (a+d)/(a+b+c+d) = (10+14)/30 = 80% 
Cohen Agreement Coefficient (K) = 0.59    95% CI: 0.30-0.88 
This coefficient measures the agreement between two different classification systems unbound 
from the agreement obtained by chance. The highest agreement is achieved for K values = 1   
 
 
  TRAP 
  Pos Neg 
 
Total 
 
Positive 
 
 
 
10 (a) 
 
3 (b) 
 
13 (a+b) 
 
TRAP 
ELISA 
 
Negative 
 
 
 
3 (c) 
 
14 (d) 
 
17 (c+d) 
Total 13 (a+c) 17 (b+d) 30 (a+b+c+d) 
 
 
 
Table 10   Monte Carlo Simulation: simulation of the probability to have a tumor after a positive 
result on TRAP ELISA with the following scenario: generalized lymphadenopathy, cytology 
positive sample, probability to have a tumor before the test = 80%, and sensitivity and specificity 
assessed with a β-distribution. 
 
K Interpretation 
< 0 No Agreement 
0.0 – 0.19 Poor Agreement 
0.20 – 0.39 Fair Agreement 
0.40 – 0.59 Moderate Agreement 
0.60 – 0.79 Substantial Agreement 
0.80 – 1.00 Almost Perfect Agreement 
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Table 11. Post-test probability outcome obtained with the Monte Carlo simulation method. 
 
Parameters Values Formula 
Sensitivity 0.71 RiskBeta(12; 5) 
Specificity 0.82 RiskBeta(14; 3) 
LR+ 4 Se/ (1-SP) 
Prob pretest (P) 0.80 Subjective prob 
Odds pretest (OptT) 4 P/(1-P) 
Odds posttest (OpsT) 16 OpsTxLR+ 
Prob posttest 0.94 OpsT/ (1+OpsT) 
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CHAPTER 8. FIGURES 
Fig 1. TRAP Specificity 
 
 
 
Fig 2. TRAP Sensitivity; Diagnostic Odds = (a*d)/(c*b) = 56 
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Fig 3. TRAP ELISA Sensitivity 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 4. TRAP ELISA Specificity  
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Figure 5. Distribution of the post-test probability. 
 Quartile distribution: 
Min 25% Median 75% Max 
79% 92% 94% 96% 99% 
 
 
 Distribution for Prob posttest/E13
 
0
2
4
6
8
10
12
14
          
 Mean=0.9406089 
0.75 0.8125 0.875 0.9375 1
 5%  90% 5%
 .89  .98 
 69
BIBLIOGRAPHY 
 
1. Autexier C. and Greider C.W. Telomerase and cancer: Revisiting the telomere 
hypothesis. Trends Biochem Sci 21: 387-391, 1996. 
2. Bergman P.J., Ogilvie G.K., and Powers B.E.: Monoclonal antibody C219 
immunohistochemistry against P-glycoprotein: Sequential analysis and predictive ability 
in dogs with lymphoma. J Vet Int Med 10:354-359, 1996. 
3. Bilaud T., Brun C., Ancelin K., Koering C.E., Laroche T., and Gilson, E. Telomeric 
localization of TRF2, a novel human telobox protein. Nat Genet 17: 236-239, 1997. 
4. Biller B.J., Kitchell B.E., and Cadile C.D. Evaluation of an assay for detecting telomerase 
activity in neoplastic tissues of dogs. Am J Vet Res 59(12):1526-1529, 1998. 
5. Blackburn E.H., and Gall J.G. A tandemly repeated sequence at the termini of the 
extrachromosomal ribosomal RNA genes in Tetrahymena. J Mol Biol 120 (1): 33-53, 
1978. 
6. Blackburn EH. Telomeres and their synthesis. Science 249 (4968): 489-490, 1990. 
7. Blackwood L., Sullivan M., and Lawson H. Radiographic abnormalities in canine 
multicentric lymphoma: A review of 84 cases. J Small Anim Pract 38:62-69, 1997. 
8. Blasco M.A., and Greider, C.W. Telomere shortening and tumor formation by mouse 
cells lacking telomerase RNA. Cell 91: 25-34, 1997. 
9. Bodnar A.G., Ouellette M., Frolkis M., Holt S.E., Chiu C.P., Morin G.B., Harley C.B., 
Shay J.W., Lichtsteiner S., and Wright W.E. Extension of life-span by introduction of 
telomerase into normal human cells. Science. 279(5349):349-352, 1998. 
10. Broccoli D., Young J.W., and De Lange T. Telomerase activity in normal and malignant 
hematopoietic cells. Proc Natl Acad Sci 92: 9082-9086,1995. 
11. Bryan M.T., Englezou A., Gupta J., Bacchetti S. and Reddel RR. Telomere elongation in 
immortal human cells without detectable telomerase activity. EMBO J (17): 4240-4248, 
1995. 
12. Bunn C.L., and Tarrant G.M. Limited lifespan in somatic cell hybrids and cybrids Exp 
Cell Res 127:385-396, 1980. 
13. Carioto L.M., Kruth S.A., Betts D.H., and King W.A. Telomerase activity in clinically 
normal dogs and dogs with malignant lymphoma. Am J Vet Res  62(9):1442-1446, 2001. 
 70
14. Carter R.F., and Valli V.E.O. Advances in the cytologic diagnosis of canine lymphoma. 
Semin Vet Med Surg (Small Anim) 3:167-175, 1988. 
15. Colgin L.M., and Reddel R.R. Telomere maintenance mechanisms and cellular 
immortalization. Curr Opin Genet Dev 9:97-103, 1988. 
16. Corey D.R. Peptide nucleic acids: expanding the scope of nucleic acid recognition. 
Trends Biotechnol 15:224-229, 1997. 
17. Counter C.M., Avilion A.A., LeFeuvre C.E., Stewart N.G., Greider C.W., Harley C.B., 
and Bacchetti S. Telomere shortening associated with chromosome instability is arrested 
in immortal cells which express telomerase activity. EMBO J 11 (5):1921-1929, 1992. 
18. Dashe R., Fiedler W., and Ernst G. Telomeres and telomerases: biological and clinical 
importance. Clin Chem 43:708-714, 1997. 
19. Dernburg A.F., Sedat J.W., Zacheus Cande W., and Bass H.W. in Telomeres (Blackburn 
E.H., and Greider C.W.,eds.) Cold Spring Harbor Laboratory Press, Cold spring Harbor, 
NY, pp. 295-338, 1995. 
20. Elmore L.W., Forsythe H.L., Ferreira-Gonzalez A., Garrett C.T., Clark G.M., and Holt 
S.E.. Real-time quantitative analysis of telomerase activity in breast tumor specimens 
using a highly specific and sensitive fluorescent-based assay. Diagnostic Molecular 
Pathology 11(3):177-185, 2002.  
21. Fedoroff O.Y., Salazar M., Han H., Chemeris V.V., Kerwin S.M. and Hurley L.H. NMR-
based model of a telomerase inhibiting compound bound to G-quadruplex DNA. 
Biochemistry 37:12367-12374, 1998. 
22. Fushimi K., Iijima M., Gao C., Kondo T., Tsuji T., Hashimoto T., Mihara K., and Namba 
M. Int J Cancer 70:135-140, 1997. 
23. Greider C.W., and Blackburn E.H. Telomeres, telomerase and cancer. Sci Am  274(2):92-
97, 1996. 
24. Hahn W.C., Counter C.M., Lunberg A.S., Beijersbergen R.L., Brooks M.W., and 
Weinberg R.A. Creation of human tumour cells with defined genetic elements. Nature 
400 (6743): 464-468, 1999. 
25. Hahn W.C., Stewart S.A., Brooks M.W., York S.G., Eaton E., Kurachi A., Beijersbergen 
R.L., Knoll J.H., Meyerson M., and Weinberg R.A. Inhibition of telomerase limits the 
growth of human cancer cells. Nat Med 5:1164-1170, 1999. 
26. Hamad N.M., Banik S.S., and Counter C.M. Mutational analysis defines a minimum level 
of telomerase activity required for tumorigenic growth of human cells. Oncogene 
21(46):7121-7125, 2002. 
 71
27. Hamilton S.E., Pitts A.E., Katipally R.R., Jia X., Rutter J.P., Davies B.A., Shay J.W., 
Wright W.E., and Corey D.R. Identification of  determinants for inhibitor binding within 
the RNA active site of human telomerase using PNA scanning . Biochemistry 36:11873-
11880, 1997. 
28. Hamilton S.E., Simmons C.G., Kathiriya I.S., and Corey D.R. Cellular delivery of 
peptide nucleic acid and inhibition of human telomerase. Chem Biol 6:343-351, 1999. 
29. Henderson S., Allsopp R., Spector D., Wang S.S., and Harley C. In situ analysis of 
changes in telomere size during replicative aging and cell proliferation. J Cell Biol 134:1-
12, 1996. 
30. Hipple A.K., Colitz C.M.H., Mauldin G.N., Cho D.Y. Telomerase activity, telomere 
lenghts and related immunohistochemical properties of normal canine lymph node and 
canine lymphoma. Veterinary Cancer Society 21st Annual Conference Pag.23, 2001. 
31. Hollyday R. Capire l’invecchiamento. Zanichelli editore, pp.65-69, 1995. 
32. Hou M., Xu D., Bjorkholm M., and Gruber A. Real-time quantitative telomeric repeat 
amplification protocol assay for the detection of telomerase activity. Clin Chem (3):519-
524, 2001. 
33. Hu B.T., and Insel R.A. Up-regulation of telomerase in human B lymphocytes occurs 
independently of cellular proliferation and with expression of the telomerase catalytic 
subunit. Eur J Immunol 29:3745-3753, 1999. 
34. Ijdo J.W., Wells R.A., Baldini A., and Reeders S.T. Improved telomere detection using a 
telomere repeat probe (TTAGGG)n generated by PCR. Nucleic Acids Res 19:4780, 1991. 
35. Izbicka E., Wheelhouse R.T., Raymond E., Davidson K.K., Lawrence R.A., Sun D., 
Windle B.E., Hurley L.H., and Von Hoff D.D. Effects of cationic porphyrins as G-
quadruplex interactive agents in human tumor cells. Cancer Res 59:639-644, 1999. 
36. Jiao M.U., Li Xin W.E.I. Telomere and telomerase in oncology. Cell Research 12(1):1-7, 
2002. 
37. Kanazawa Y., Ohkawa K., Ueda K., Mita E., Takehara T., Sasaki Y., Kasahara A., and 
Hayashi N. Hammerhead ribozyme-mediated inhibition of telomerase activity in extract 
of human hepatocellular carcinoma cells. Biochem Biophys Res Commun 225:570-576, 
1996. 
38. Kartner N., Riordan J.R., and Ling V. Cell surface P-glycoprotein associated with 
multidrug resistance in mammalian cell liver. Science 221:1285-1288, 1983. 
39. Keller E., MacEwen E., Rosenthal R., Helfand S.C., and Fox L.E. Evaluation of 
prognostic factors and sequential combination chemotherapy for canine lymphoma. J Vet 
Int Med 7:289-295, 1993. 
 72
40. Kim M.Y., Vankayalapati H., Shin-Ya K., Wierzba K., and Hurley L.H. Telomestatin, a 
potent telomerase inhibitor that interacts quite specifically with the human telomeric 
intramolecular g-quadruplex. J Am Chem Soc 124(10):2098-2099, 2002. 
41. Kim N.W., and Wu F. Advances in quantification and characterization of telomerase 
activity by the telomeric repeat amplification protocol (TRAP). Nucleic Acids Res 
25:2595-2597, 1997. 
42. Klapper W., Parwaresch R., and Krupp G. Telomere biology in human aging and aging 
syndromes. Mechanisms of Aging and Development 122:695-712, 2001. 
43. Kolquist K.A., Ellisen L.W., Counter C.M., Meyerson M., Tan L.K., Weinberg R.A., 
Haber D.A., and Gerald W.L. Expression of TERT in early premalignant lesions and a 
subset of cells in normal tissues. Cancer Research 56:645-650, 1998. 
44. Kondo S., Kondo Y., Li G., Silverma R.H., and Cowell J.K. Targeted therapy of human 
malignant glioma in a mouse model by 2-5A antisense directed against telomerase RNA. 
Oncogene 16:2243-2248, 1998. 
45. Kosciolek B.A., and Rowley P.T. Human lymphocyte telomerase is genetically regulated. 
Genes Chromosomes and Cancer 21:124-130, 1998. 
46. Krejci K., and Kock J. Improved detection and comparative sizing of human 
chromosomal telomeres in situ. Chromosoma 107:198-203, 1998. 
47. Lansdorp P.M., Verwoerd N.P., van de Rijke F.M., Dragowska V., Little M.T., Dirks 
R.W., Raap A.K., and Tanke H.J. Heterogeneity in telomere length of human 
chromosomes. Hum Mol Genet 5, 685-691, 1996. 
48. Lee H.W., Blasco M.A., Gottlieb G.J., Horner J.W., Greider C.W. and DePinho R.A 
Essential role of mouse telomerase in highly proliferative organs. Nature 392 :569-574, 
1998. 
49. Levy M.Z., Allsopp R.C., Futcher A.B., Greider C.W., and Harley C.B. Telomere end-
replication problem and cell aging. J Mol Biol 225 (4):951-960, 1992. 
50. Lin Z., Lim S., Viani M.A., Sapp M., and Lim M.S. Down-regulation of telomerase 
activity in malignant lymphomas by radiation and chemotherapeutic agents. Am J Pathol 
159(2): 405-410, 2001. 
51. Linder S., and Marshall H. Immortalization of primary cells by DNA tumor viruses. Exp 
Cell Res 191(1):1-7, 1990. 
52. Lingner J., Hughes T.R., Shevchenko A., Mann M., Lundblad V., and Cech T.R. Reverse 
Transcriptase Motifs in the Catalytic Subunit of Telomerase. Science 276 (5312):561-
567, 1997. 
 73
53. Liu Y., Snow B.E., Hande M.P., Yeung D., Erdmann N.J., Wakeham A., Itie A., 
Siderovsky D.P., Landsorp P.M., Robinson M.O., and Harrington L. The telomerase 
reverse transcripatase is limiting and necessary for telomerase function in vivo. Curr Biol 
22:1459-1462, 2000. 
54. Luderus M.E., van Steensel B., Chong L., Sibon O.C., Cremers F.F., and de Lange T. 
Structure, subnuclear distribution, and nuclear matrix association of the mammalian 
telomeric complex. J Cell Biol 135:867-881, 1996. 
55. Macieira-Coelho A. Markers of 'cell senescence'. Mech Ageing Dev 104(2):207-211, 
1998. 
56. Maclean K., Rogan E.M., Whitaker N.J., Chang A.C.M., Rowe P.B., Dalla-Pozza L., 
Symonds G., and Redeel R.R., In vitro transformation of Li-Fraumeni syndrome 
fibroblasts by SV40 large T antigen mutants Oncogene 9:719-725, 1994. 
57. MacNamara B., Wang W., Chen Z., Hou M., Mazur J., Gruber A., and Porwit-
MacDonald A. Telomerase activity in relation to pro- and anti-apoptotic proteins 
expression in high grade non-Hodgkin’s lymphomas. Haematologica 86(4):386-93, 2001. 
58. Madewell B.R. Hematological and bone marrow cytological abnormalities in 75 dogs 
with malignant lymphoma. J Am Anim Hosp Assoc 22:235-240, 1986. 
59. Martens U.M., Zijlmans J.M., Poon S.S., Dragowska W., Yui J., Chavez E.A., Ward 
R.K., and Landsdorp P.M. Short telomeres in human chromosome 17p. Nat Genet 18:76-
80, 1998. 
60. Mata J.E., and Iversen P.L. A hexameric phosphorothioate oligonucleotide telomerase 
inhibitor arrests growth of Burkitt’s lymphoma cells in vitro and in vivo. Tox App 
Pharmacol 144:189-197, 1997. 
61. Meyne J., and Moyzis R.K. In situ hybridization using synthetic oligomers as probes for 
centromeres and telomeres, in Methods in Molecular Biology, vol. 33. (Choo, K.H.A., 
ed.) Humana Press, Totowa, NJ, pp. 63, 1994. 
62. Mondello C. I telomeri. BioTec 1:4, 1998. 
63. Morin G.B. Is Telomerase a universal cancer target? J Natl Cancer Inst 87 (12): 859-861, 
1995. 
64. Morrison W.B. Cancer in dogs and cats. Medical and Surgical Management. Lippincott 
Williams and Wilkins, pp.667-697, 1998 
65. Nakamura T.M., Cooper J.P., and Cech T.R. Two modes of survival of fission yeast 
without telomerase. Science 282:493-496, 1998. 
 74
66. Nakamura T.M., Morin G.B., Chapman K.B., Weinrich S.L., Andrews W.H., Lingner J., 
Harley C.B., and Cech T.R. Telomerase catalytic subunit homologs from fission yeast 
and human. Science 277 :955-959 1997. 
67. Nakayama J.I., Tahara H., Tahara E., Ide T., and Ishikawa F. Telomerase activation by 
hTRT in human normal fibroblasts and hepatocellular carcinoma. Nat Genet 18: 65-68, 
1998. 
68. Nasir L., Devlin P., Mckevitt T., Rutteman G., and Argyle D.J. Telomere lengths and 
telomerase activity in dogs tissues: a potential model system to study human telomere 
and telomerase biology. Neoplasia (4):351-359, 2001. 
69. Nilsson P., Mehle C., Remes K., and Roos G. Telomerase activity in vivo in human 
malignant hematopoietic cells. Oncogene  9:3043-3048, 1994. 
70. Norrback K.F., and Roose G. Telomeres and telomerase in normal and malignant 
hematopoietic cells. Eur J Cancer 33:774-780, 1997. 
71. Norrback K.F., Dahlenborg K., Carlsson R., and Roos G. Telomerase activation in 
normal B lymphocytes and non-Hodgkin’s lymphomas. Blood 88(1):222-229, 1996. 
72. Norrback K.F., Hultdin M., Dahlenborg K., Osterman P., Carlsson R., and Roos G. 
Telomerase regulation and telomere dynamics in germinal centers. Eur J Haematol 67: 
309-317, 2001.  
73. Norton J.C., Piatyszek M.A., Wright W.E., Shay J.W. and Corey D.R. Inhibition of 
human telomerase activity by peptide nucleic acids. Nat Biotechnol 14:615-619, 1996. 
74. Pereira- Smith O.M., and Smith J.R. Evidence for the recessive nature of cellular 
immortality.  Science 221:964-966, 1983. 
75. Pitts A.E. and Corey D.R. The telomerase challenge- an unusual problem in drug 
discovery. Drug Discovery Today 4:155-161, 1999. 
76. Price C.M. Synthesis of the telomeric C-Strand: A review. Biochemistry (Mosc) 
62(11):1216-1223, 1997. 
77. Rhyu M.S. Telomeres, telomerase, and immortality. J Natl Cancer Inst  87 (12): 884-94, 
1995. 
78. Rogan E.M., Bryan T.M., Hukku B., Maclean K., Chang A.C.M., Moy E.L., Englezou 
A., Warneford S.G., Dalla-Pozza L., and Reddel R.R. Mol Cell Biol 15: 4745-4753, 1995. 
79. Ruslander D.A., Gebhard D.H., Tompkins M.G., Grindem C.B., and Page R.L. 
Immunophenotypic characterization of canine lymphoproliferative disorders. In Vivo 
11(2):169-172, 1997. 
 75
80. Shay J.W., Van Der Haegen B.A., Ying Y., and Wright W.E. Exp Cell Res 209: 45-52, 
1993. 
81. Singer M.S., and Gottschling D.E. TLC1: template RNA component of Saccharomyces 
cerevisiae telomerase. Science 266:404-409, 1994. 
82. Skulachev V.P. Aging is a specific biological function rather than the result of a disorder 
in complex living systems: biochemical evidence in support of Weismann’s hypothesis. 
Biochemistry (Mosc) 62(11):1191-5, 1997. 
83. Skulachev V.P. Programmed death phenomena: From organelle to organism. Ann NY 
Acad Sci 959:214-237, 2002. 
84. Spangler E.A., Rogers K.S., Thomas J.S., Pustejovsky D., Boyd S.L., and Shippen D.E. 
Telomerase enzyme activity as a diagnostic tool to distinguish effusions of malignant and 
benign origin. J Vet Intern Med 14(2):146-150, 2000. 
85. Starrak G.S., Berry C.R., Page R.L., Johnson J.L., and Thrall D.E. Correlation between 
thoracic radiographic changes and remission/survival duration in 270 dogs with 
lymphosarcoma. Vet Radiol Ultrasound 38: 411-418, 1997. 
86. Sun D., Thompson B., Cathers B.E., Salazar M., Kerwin S.M., Trent J.O., Jenkins T.C., 
Neidle S., and Hurley L.H. Inhibition of human telomerase by a G-quadruplex-interactive 
compound. J Med Chem 40:2113-2116, 1997. 
87. Tatematsu K., Nakayama J., Danbara M., Shionoya S., Sato H., Omine M., and Ishikawa 
F. A novel quantitative “stretch PCR Assay” that detects a dramatic increase in 
telomerase activity during the progression of myeolid leukemias. Oncogene 13:2265-
2274, 1996. 
88. Teske E. Canine malignant lymphoma: A review and comparison with human 
non-Hodgkin's lymphoma. Vet Quart (16)4:209-219, 1994. 
89. Therkelsen, A.J., Nielsen A., Koch J., Hindkjaer J., and Kolvraa S. Staining of human 
telomeres with primed in situ labelling (PRINS). Cytogenet Cell Genet 68: 115-118, 
1995. 
90. Van Steensel B., De Lange T. Control of telomere length by the human telomeric protein 
TRF1. Nature 385 (6618):740-743, 1997. 
91. Wan M.S.K., Fell P.L., and Akhtar S. Synthetic 2’-O-methyl modified hammered 
ribozymes targeted to the RNA component of telomerase as a sequence-specific 
inhibitors of telomerase activity. Antisense Nucleic Acid Drug Dev 8:309-317, 1998. 
92. Wang J., Zhang B., Yang S., He X., Han J., Li B., and Hou L. Development of a 
monoclonal antibody for neutralization of human telomerase activity. Hybrid 
Hybridomics 21(4):295-300, 2002. 
 76
93. Wei R., and Younes M. Immunohistochemical detection of telomerase reverse 
transcriptase in colorectal adenocarcinoma and benign colonic mucosa. Hum Pathol  
33(7):693-696, 2002. 
94. Wellinger R.J., and Sen D. The DNA structures at the ends of eukaryotic chromosomes. 
Eur J Cancer 33 : 735-749, 1997. 
95. Withrow and MacEwen. Small Animal Clinical Oncology. Third Edition, pp.558-589, 
2001. 
96. Wright W.E., Pereira- Smith O.M., and Shay J.W. Mol Cell Biol  9:3088-3092. 1989. 
97. Wu K., Lund M., Bang K., and Thestrup-Pedersen K. Telomerase activity and telomere 
length in lymphocytes from patients with cutaneous T-cell lymphoma. Cancer 
86(6):1056-1063, 1999. 
98. Xu S.Q., He M., Yu H.P., Wang X.Y., Tan X.L., Lu B., Sun X., Zhou Y.K., Yao Q.F., 
Xu Y.J., and Zhang Z.R. Bioluminescent Method for Detecting Telomerase Activity. 
Clinical Chemistry. 48(7):1016-1020, 2002. 
99. Yamada O., Motoji T., and Mizoguchi H. Up-regulation of telomerase activity in human 
lymphocytes. Biochim Biophys Acta 1314(3):260-6, 1996. 
100. Yang S., Zhang B., Wang J., Liao S., Han J., Wei J., and Hou L. Monoclonal antibodies 
against human telomerase reverse transcriptase: Preparation, characterization, and 
application. Zhonghua Bing Li Xue Za Zhi 31(1):50-4, 2002. 
101. Yang S., Zhang B., Wang J., Liao S., Han J., Wei J., and Hou L. Monoclonal antibodies 
against human telomerase reverse transcripatase (hTERT): Preparation, characterization, 
and application. Hybridoma 20(4):249-255, 2001. 
102. Yashima K., Piatyszek M.A., Saboorian H.M., Virmani A.K., Brown D., Shay J.W., 
Gazdar A.F. Telomerase activity and in situ telomerase RNA expression in malignant and 
non-malignant lymph nodes. J Clin Pathol 50(2):110-117, 1997. 
103. Yazawa M., Okuda M., Setoguchi A., Iwabuchi S., Nishimura R., Sasaki N., Masuda K., 
Ohno K., and Tsujimoto H. Telomere length and telomerase activity in canine mammary 
gland tumors. Am J Vet Res 62(10):1539-1543, 2001. 
104. Yazawa M., Okuda M., Setoguchi A., Nishimura R., Sasaki N., Hasegawa A., Watari T., 
and Tsujimoto H. Measurement of Telomerase Activity in Dog Tumors. J Vet Med Sci 
61(10):1125-1129,1999. 
105. Yokoyama Y., and Tamaya T. Attenuation of telomerase activity by a hammered 
ribozyme targeting the template region of telomerase RNA in endometrial carcinoma 
cells. Cancer Res 58:5406-5410, 1998. 
 77
106. Yu G-L., Bradley J.D., Attardi L.D. and Blackburn E.H. In vivo alteration of telomere 
sequences and senescence caused by mutated Tetrahymena telomerase RNAs. Nature 
344 :126-132, 1990. 
107. Yuan X., Zhang B., Ying J.M., Jin Y.Y., and Hou L. Expression of telomerase genes in 
human tumors. Chin J Pathol 29:16-19, 2000. 
108. Zhang K., Mar V., Zhou W., Harrington L., and  Robinson M.O. Telomere shortening 
and apoptosis in telomerase-inhibited human tumor cells. Genes Dev 13:2388-2399, 
1999. 
109. Zijlmans J.M., Martens U.M., Poon S.S., Raap A.K., Tanke H.J., Ward R.K., Lansdorp 
P.M. Telomeres in the mouse have large interchromosomal variations in the number of 
T2AG3 repeats. Proc Natl Acad Sci USA 94:7423-7428, 1997. 
 
 
